Introduction {#s1}
============

The function of T cells is to mount an immune response to foreign ligands, such as derived from bacteria or viruses, but not to respond to self ligands stemming from the body's own cells. These ligands are composed of a foreign peptide presented by major histocompatibility complexes molecules (pMHC) on the own cells. Activation of a T cell is initiated when foreign pMHC bind to the T cell receptor (TCR) on the T cell surface. The pMHC-TCR binding event stimulates intracellular signaling pathways, such as calcium influx into the cytosol, leading to the functional responses of the T cell ([@bib19]). Self peptides on MHC (self pMHCs) also bind to the TCR and are important for the development and survival of naïve T cells, but do not trigger an immune response as seen for foreign peptides on MHC ([@bib22]). This discrimination between foreign and self pMHC correlates with the affinity of the ligand-TCR interaction, in that foreign, stimulatory pMHCs bind with higher affinity to the TCR than non-stimulatory pMHC ([@bib22]; [@bib75]). However, how the affinity of a ligand is determined by the cell to generate a T cell response or not remains enigmatic ([@bib16]). Note that in case of pMHC binding to T cells other processes than the pure pMHC-TCR interaction are involved, such as interactions with the co-receptors CD8 or CD4; thus, the terms 'apparent affinity' or 'potency' might be more suitable when describing these complex binding events.

One model is kinetic proofreading (KPR), which originally described the specificity by which the genetic code is read in protein synthesis ([@bib33]) and inspired a similar theoretical model for ligand discrimination in T cells ([@bib54]). In KPR the T cell does not simply measure the amount of ligand-bound TCRs (called occupancy model), but monitors the dynamics of the binding events. These dynamics can be described by the on-rate and the half-life of the interaction. The KPR model proposes that a long half-life of the ligand-TCR interaction, such as seen for high affinity pMHC, allows a series of biochemical reactions to be completed that eventually trigger downstream signaling. By contrast, a low affinity ligand detaches before an activatory signal is produced and the TCR then reverts quickly to the initial inactive state, thus not initiating T cell activation. Although the half-life is the decisive factor, it was recently shown that the on-rate also plays a role ([@bib5]; [@bib29]; [@bib47]). If the on-rate is very fast a ligand that has detached can rapidly rebind to the same TCR before the first biochemical reactions are reverted. Again, the duration of the binding event, in this case interrupted by short dissociations, is the relevant parameter.

The KPR model has also been extended to include feedback and feed-forward loops in the signaling network below the TCR ([@bib6]; [@bib16]; [@bib25]; [@bib44]; [@bib62]). Inclusion of these signaling network loops improved the mathematical description of the observed sharp ligand discrimination threshold, when relating ligand half-life to T cell activation. At the same time, the high sensitivity of the T cells towards low numbers of ligands (1--10 molecules) was retained ([@bib35]; [@bib61]).

To get experimental insight into the mechanism of ligand discrimination by T cells, pMHC or TCRs have been mutated at the binding sites to generate ligand-TCR pairs of different affinities and half-lives ([@bib5]; [@bib6]; [@bib20]; [@bib23]; [@bib25]; [@bib29]; [@bib32]; [@bib37]; [@bib39]; [@bib43]; [@bib44]). Although such studies are broadly consistent with KPR, other biophysical parameters, such as the free binding energy, geometry of the interaction ([@bib2]), conformational changes at the TCR ([@bib24]; [@bib28]; [@bib63]) and the ability to withstand pulling ([@bib41]; [@bib48]), might also have been changed along with the affinity, and therefore alternative models of ligand discrimination cannot be ruled out. Unfortunately, no method to specifically modulate only the dynamics of ligand-receptor interactions is currently available. Thus, in order to disentangle the half-life from these other parameters, we engineered an optogenetic system in which the duration of ligand binding to the TCR can be remotely controlled in a reversible manner (ON-OFF switch), called the opto-ligand-TCR system.

Our opto-ligand-TCR approach harnesses the PhyB-PIF (phytochrome B-PhyB interacting factor) protein pair from *Arabidopsis thaliana* ([@bib10]; [@bib45]; [@bib79]). In this pair, the photoreceptor PhyB is the light-responsive element, due to its chromophore phycocyanobilin, which undergoes a conformational cis-trans isomerization when absorbing photons of the appropriate wavelength. Upon illumination with 660 nm light, PhyB switches to its ON state in which it interacts with PIF6 with a nanomolar affinity ([@bib45]). With 740 nm light, PhyB undergoes a conformational transition to the OFF state preventing binding to PIF6. This light-dependent protein-protein interaction was utilized in several optogenetic applications ([@bib42]), such as the control of protein or organelle localization ([@bib3]; [@bib13]; [@bib45]), intracellular signaling ([@bib79]), nuclear transport of proteins ([@bib12]), cell adhesion ([@bib9]; [@bib85]) or gene expression ([@bib57]). Using high intensity light, the PhyB-PIF interaction can be switched ON and OFF within seconds ([@bib45]; [@bib52]; [@bib69]). Importantly for our study, at continuous 660 nm illumination the individual PhyB molecules constantly switch between the ON and OFF states, again in the order of seconds, thus being within the range of the estimated KPR times ([@bib52]; [@bib69]).

We and others have previously fused binding domains to the ectodomain of the TCRβ subunit; either a single chain Fv fragment ([@bib55]) or a single strand DNA oligonucleotide ([@bib76]). Indeed, the chimeric TCRs were expressed on the cell surface and were activated via the appended binding domains. Importantly, ligand discrimination also occurred when using the DNA-TCR; i.e., a low affinity binder to the DNA did not evoke TCR stimulation and a high affinity binder did ([@bib76]). This clearly showed that ligands do not need to bind to the canonical pMHC binding site within the TCR and that co-receptors are not required for ligand discrimination. It should be noted that the developmental state of the T cell can modulate the discrimination process as do the co-receptors (CD8 or CD4) or the expression levels of intracellular signaling molecules ([@bib6]; [@bib21]; [@bib49]; [@bib51]; [@bib71]).

Here we fused the first 100 amino acids of PIF6 together with GFP to the ectodomain of TCRβ and used the first 651 amino acids of PhyB in a tetramerized form as the ligand ([Figure 1](#fig1){ref-type="fig"}). Using continuous 660 nm light of different intensities to modulate the dynamics of PhyB tetramer binding to the TCR and calcium influx as a readout we find that there is an intensity threshold: at lower intensities and longer ligand-TCR half-lives the T cell is activated and at higher intensities and shorter half-lives the cell is not activated. Using a mathematical model of KPR we show that the threshold half-life in our opto-ligand-TCR system is 8 s.

![Engineering a light-controlled switch for the ligand-TCR interaction: the opto-ligand-TCR system.\
Light of 660 nm and 740 nm wavelength reversibly switches PhyB between the OFF and ON states. In the ON state PhyB tetramers (PhyBt) bind to and cluster GFP-PIF^S^-TCRs leading to signaling and the activation of the T cell. The red dot indicates the fluorophore-coupled streptavidin tetramer.](elife-42475-fig1){#fig1}

Results {#s2}
=======

The first aim of our study was to establish an optogenetic system in which ligand binding to the TCR can be reversibly controlled by light ([Figure 1](#fig1){ref-type="fig"}).

Engineering of the opto-ligand-TCR system: the ligand {#s2-1}
-----------------------------------------------------

The light-responsive N-terminal 651 amino acids of *A. thaliana* PhyB (PhyB~1-651~) have been used as an optogenetic tool ([@bib3]; [@bib9]; [@bib12]; [@bib13]; [@bib36]; [@bib45]; [@bib58]; [@bib79]) and the photobiology of this fragment has been described previously ([@bib69]). Here we used this PhyB form as a ligand. PhyB~1-651~ fused to the biotinylation site Avitag ([@bib11]) and a His~6~-tag ([Figure 2A](#fig2){ref-type="fig"}) was produced in *E. coli.* Additionally, the bacteria were engineered to produce the cyanobacterial version of the phytochrome chromophore, phycocyanobilin ([@bib26]; [@bib69]). PhyB~1-651~-Avitag-His~6~, called PhyB in the remainder of this article, was isolated by Ni^2+^-affinity chromatography ([@bib69]). We then tested the functionality of PhyB through its light-dependent interaction with PIF6. To this aim, we produced the first 100 amino acids of *A. thaliana* PIF6 (PIF6~1-100~), which were shown to be sufficient for photoreversible PhyB binding with nanomolar affinity ([@bib77]), as a fusion protein with the maltose-binding protein and a His~6~-tag \[MBP-PIF6~1-100~-His~6~, from now on called MBP-PIF(wt)\]. After illuminating a mixture of PhyB and an excess MBP-PIF(wt) with saturating 660 nm light, 70% of the PhyB molecules were complexed with PIF as depicted by a shift in elution from a size exclusion chromatography column ([Figure 2B](#fig2){ref-type="fig"}). This was not the case when the proteins were exposed to 740 nm light. Since at photoequilibrium under 660 nm light only 80% of the PhyB molecules are in the ON state ([@bib10]; [@bib69]), we conclude that the majority of PhyB molecules were functionally active.

![Production of PhyB tetramers.\
(**A**) Schematics of the PhyB~1-651~ construct and the PhyB tetramers. PCB = phycocyanobilin. (**B**) Purified PhyB was illuminated with 660 nm light \[PhyB(660)\] and added in a 1:2 molar ratio to MBP-PIF(wt). The proteins were separated by gel filtration and PhyB was detected by its absorbance at the isosbestic point of 671 nm. PhyB molecules around 14.5 ml elution volume are the free PhyB molecules and the ones around 12.5 ml are the PhyB-MBP-PIF complexes. As controls, PhyB illuminated with 740 nm light \[PhyB(740)\] plus MBP-PIF(wt) and PhyB alone was only detected at 14.5 ml elution volume. Results show one experiment of n \> 3. (**C**) Affinity chromatography-purified PhyB was mixed in a 10:1 molar ratio with streptavidin-DyLight650, incubated for 2 hr at room temperature and the formed PhyB tetramers (PhyBt) were isolated from monomers using size-exclusion chromatography. The elution of PhyB was monitored via its absorbance at 365 nm. Results show one experiment of n \> 3.](elife-42475-fig2){#fig2}

Although soluble TCR ligands are active as dimers ([@bib14]; [@bib17]; [@bib56]; [@bib55]), tetrameric pMHC based on streptavidin are routinely used to stimulate the TCR ([@bib7]) and to obtain insight into ligand discrimination by T cells ([@bib73]; [@bib72]). Thus, we wanted to construct PhyB tetramers (PhyBt) to be used as ligands in our system ([Figure 1](#fig1){ref-type="fig"}). To this end, biotinylated PhyB was tetramerized using fluorophore-coupled streptavidin. After separating the tetramers from monomers by size exclusion chromatography ([Figure 2C](#fig2){ref-type="fig"}), we obtained purified PhyBt that we used in this work.

Engineering of the opto-ligand-TCR system: the TCR {#s2-2}
--------------------------------------------------

Next, we engineered a PIF-fused TCR that can bind to and be activated by PhyBt when the PhyB molecules are in the ON (but not in the OFF) state ([Figure 1](#fig1){ref-type="fig"}). In plants PIF6 is produced in the cytoplasm, whereas in our system PIF6 is produced in the oxidative environment of the endoplasmic reticulum. Therefore, we mutated cysteines and N-linked glycosylation sites (Asn-X-Ser/Thr) in PIF6. We produced a panel of five different PIF6~1-100~ mutants abolishing cysteines 9 and 10 as well as asparagine 35 or serine 37 as MBP fusion proteins ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). We analyzed the interaction of PhyB with these PIF6~1-100~ mutants under limiting amounts of MBP-PIF using size exclusion chromatography ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). All mutants formed complexes with PhyB pre-illuminated with 660 nm light \[PhyB(660)\] similar to MBP-PIF(wt).

Having seen that all PIF6~1-100~ mutants interacted well with PhyB, they were fused - preceded by a signal peptide - to the N-terminus of the human HA1.7 TCRβ chain that contains a Vβ3 variable region ([@bib30]; [@bib31]) ([Figure 3A](#fig3){ref-type="fig"}). We analyzed the presence of the different PIF6~1-100~-TCRβ constructs on the cell surface following lentiviral transduction of Jurkat T cells ([@bib1]). PIF6~1-100~ C9S C10S S37A \[PIF(SSA)\] showed the highest surface presence ([Figure 3B](#fig3){ref-type="fig"}), indicating that it assembled to a complete TCR complex ([@bib4]; [@bib15]). Hence, PIF(SSA) was therefore used for all future optimizations and termed secretory PIF or PIF^S^ ([Figure 3C](#fig3){ref-type="fig"}). Surprisingly, despite the good interaction of MBP-PIF^S^ with PhyB in size-exclusion chromatography ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}), no binding of PhyBt to the PIF^S^-TCR on the surface of Jurkat cells could be detected ([Figure 3D](#fig3){ref-type="fig"}). GFP-PIF^S^-TCR cells (described below) served as a positive control for binding ([Figures 3D](#fig3){ref-type="fig"} and [4F](#fig4){ref-type="fig"} panels are from the same experiment). Furthermore, PIF^S^-TCR Jurkat cells could be stimulated to flux calcium via cross-linking of the PIF^S^-TCR using an anti-Vβ3 antibody, but not using PhyBt pre-illuminated with 660 nm light, called PhyBt(660) ([Figure 3E](#fig3){ref-type="fig"}). Consequently, although PIF^S^-TCRβ is present at the cell surface and PIF^S^ itself binds to PhyB (in the form of MBP-PIF), PIF^S^ loses its binding capacity towards PhyB when it is fused to the TCR and exposed on the T cell's surface.

![Selection of PIF^S^ that can be expressed together with the TCR.\
(**A**) Schematics of the PIF-TCRβ constructs, including wild-type and mutant PIF. SP depicts the signal peptide and the arrow the signal peptidase cleavage site. The schematic constructs are drawn to scale with the scale bar indicated. (**B**) The presence of the different PIF-TCRs and a single chain variable fragment (scFv)-TCR on the cell surface was measured in lentivirally transduced Jurkat cells together with the parental cell line using an anti-Vβ3 antibody (Jovi3) via flow cytometry. The median fluorescence intensity (MFI) averaged for three experiments ± SEM is depicted. (**C**) Scheme of PIF^S^-TCRβ as integrated into the TCR. (**D**) 100 nM phycoerythrin (PE)-labeled PhyBt pre-illuminated with 660 nm or 740 nm light were incubated with Jurkat, PIF^S^-TCR Jurkat and GFP-PIF^S^-TCR cells and binding detected by flow cytometry. Numbers depict the % of cells in the respective quadrant. Results show one experiment of n = 3. (**E**) PIF^S^-TCR cells were labeled with Indo-1 and calcium influx measured by flow cytometry. 100 nM PhyBt(660) (orange) or 1 µg/ml anti-Vβ3 antibody (blue) were added as stimuli. Their addition is marked by an arrow and the illumination procedure by a bar above the graph (grey = dark). Results show one experiment of n \> 3.](elife-42475-fig3){#fig3}

![Engineering of the GFP-PIF^S^-TCR.\
(**A**) Schematics of the GFP-PIF^S^-TCRβ constructs, including three different furin cleavage sites (F1, F2, F3) or omitting any cleavage site (noF). SP depicts the signal peptide, the arrow the signal peptidase cleavage site and moxGFP the [m]{.ul}onomeric GFP optimized for an [ox]{.ul}idative environment. (**B**) The surface expression of the different GFP-PIF^S^-TCRs and PIF^S^-TCR was measured in transduced Jurkat cells together with the parental cell line using an anti-Vβ3 antibody (Jovi3) via flow cytometry. (**C**) Analogous to (**B**), the amount of GFP was quantified on the surface of the different transductants using a polyclonal anti-GFP antibody via flow cytometry. (**B**) and (**C**) depict the median fluorescence intensity (MFI) averaged for three measurements ± SEM. (**D**) Scheme of GFP-PIF^S^-TCRβ as integrated into the TCR. (**E**) 100 nM phycoerythrin (PE)-labeled PhyBt pre-illuminated with 660 nm or 740 nm light were incubated with the cells indicated and binding was detected by flow cytometry. One experiment out of three is depicted displaying the average of quadruplicates ± SEM. (**F**) Together with [Figure 3D](#fig3){ref-type="fig"} these are the GFP vs PhyBt plots of the experiment quantified in (**E**).](elife-42475-fig4){#fig4}

A major difference between the functional MBP-PIF^S^ and the dysfunctional PIF^S^-TCRβ construct is the C- and N-terminal localization of PIF^S^, respectively. Thus, adding an unrelated protein to the N-terminus of PIF^S^ might rescue the PhyB-binding ability of the PIF^S^-TCR. To test this possibility, we attached a monomeric green fluorescent protein optimized for the oxidative environment of the endoplasmic reticulum (moxGFP, ([@bib18])) to the N-terminus of PIF^S^-TCRβ. We distinguished the effect of a permanently attached moxGFP or a moxGFP that is only present during folding of PIF^S^ in the endoplasmic reticulum. To this end, we added different furin protease recognition sequences (F1-F3) or a flexible linker without protease cleavage site (noF) between moxGFP and PIF^S^ ([Figure 4A](#fig4){ref-type="fig"}). The protease furin is expressed in the Golgi and would cleave off the moxGFP as the engineered TCRs are exported to the cell surface. All constructs were well expressed on Jurkat cells ([Figure 4B](#fig4){ref-type="fig"}) and showed the expected absence or presence of moxGFP on the cell surface ([Figure 4C](#fig4){ref-type="fig"}). The construct using a truncated furin site (F3) had intermediate surface moxGFP levels, indicating that moxGFP is inefficiently cleaved. PhyBt(660) hardly bound to the surface of Jurkat cells expressing GFP-F1-PIF^S^-TCR or GFP-F2-PIF^S^-TCR with efficiently cleaved moxGFP ([Figure 4E,F](#fig4){ref-type="fig"}). However, fusing moxGFP permanently to PIF^S^-TCRβ resulted in strong light-dependent binding of PhyBt to the cell surface. In line with this, GFP-F3-PIF^S^-TCR with partly cleaved GFP bound intermediate amounts of PhyBt(660). These data suggest that moxGFP has to be present at the GFP-PIF^S^-TCR on the cell surface, in order for PIF^S^ to bind to PhyBt(660). The optimized construct, moxGFP-noF-PIF^S^-TCR, will be called GFP-PIF^S^-TCR in the remainder of this article.

In conclusion, through several steps of engineering and optimization we generated the opto-ligand-TCR interaction system ([Figure 1](#fig1){ref-type="fig"}) based on the red/far-red light-regulated PhyB-PIF pair.

The GFP-PIF^S^-TCR is switched ON with 660 nm and OFF with 740 nm light {#s2-3}
-----------------------------------------------------------------------

PhyBt(660) bound to cells expressing the GFP-PIF^S^-TCR, whereas PhyBt pre-illuminated with 740 nm light \[PhyBt(740)\] did not ([Figure 4E,F](#fig4){ref-type="fig"}). Binding induced TCR signaling, since addition of PhyBt(660), but not PhyBt(740), resulted in a strong calcium influx into the cells similar to a stimulation using an anti-TCR antibody ([Figure 5A,B](#fig5){ref-type="fig"}). The experiment was done in the dark, since in the absence of any light, the PhyB molecules rest in their state (ON or OFF) for time scales exceeding the duration of the calcium experiments ([@bib70]; [@bib69]). 660 nm light alone in the absence of PhyBt or GFP-PIF^S^-TCR did not evoke signaling; similarly Jurkat cells not expressing the GFP-PIF^S^-TCR could not be stimulated with PhyBt(660) ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Both experiments show that the light acted through inducing PhyBt binding to GFP-PIF^S^-TCR. Furthermore, as seen with soluble pMHC ligands ([@bib14]; [@bib17]; [@bib55]), PhyB monomers (in contrast to tetramers) could not stimulate calcium influx ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Lastly, stimulation with bead-coupled PhyBt(660) in the dark resulted in up-regulation of the activation marker CD69 ([Figure 5C](#fig5){ref-type="fig"}). Together these data show that light-mediated PhyBt-binding to GFP-PIF^S^-TCR induced TCR signaling and T cell activation.

![The opto-ligand-TCR can be switched ON and OFF.\
(**A**) GFP-PIF^S^-TCR cells were labeled with Indo-1 and calcium influx measured by flow cytometry. The arrow marks the addition of the stimuli indicated, and the grey rectangle the absence of any light. Results show one experiment of n \> 3. (**B**) Calcium influx into GFP-PIF^S^-TCR cells stimulated with anti-Vβ3, PhyBt(660), PhyBt(740) or PBS was measured as in (A). Results show one experiment of n \> 3. (**C**) GFP-PIF^S^-TCR Jurkat cells were incubated with PhyBt bound to sepharose beads after a 30 s 660 nm or 740 nm light pulse for 6 hr. Expression of CD69 was quantified by flow cytometry using an APC-labeled anti-CD69 antibody. Data points depict two experiments. ([**D**]{.smallcaps}) Calcium influx was measured as in (A). PhyBt(660) induced calcium influx (blue and orange lines). After 2 min a 1 s short pulse of 100% intensity 740 nm light (red break in the grey bar) terminated the calcium response (blue line). Addition of PhyBt(740) did not induce calcium influx (red line). Results show one experiment of n \> 3.](elife-42475-fig5){#fig5}

The PhyB-PIF system allows the rapid switching between the ON and OFF states in both directions. When we switched PhyBt from the ON to the OFF state by a 1 s pulse of 740 nm light, we stopped the ongoing calcium response initially evoked by PhyBt(660) ([Figure 5D](#fig5){ref-type="fig"}), demonstrating that our system is reversible.

The intensity of continuous 660 nm light determines GFP-PIF^S^-TCR activation {#s2-4}
-----------------------------------------------------------------------------

Having established the opto-ligand-TCR system, the second aim of our study was to test the kinetic proofreading (KPR) model.

The KPR model predicts that the half-life of the ligand-TCR interaction determines TCR signaling. Here, we wanted to implement a protocol to control this half-life by light and study the consequences for TCR signaling. To this end, we exploited the property of PhyB that its continuous exposure to 660 nm light triggers both the switch from PhyB OFF to ON and the reverse switch from ON to OFF ([Figure 6A](#fig6){ref-type="fig"}) as the absorption spectra of both PhyB states partially overlap ([@bib64]). Thus, each individual PhyB molecule constantly shuttles between the ON and OFF state under 660 nm light, with high 660 nm intensities leading to a faster shuttling rate and thus to shorter binding duration (note that in [Figure 5](#fig5){ref-type="fig"} continuous light was not used and the PhyB molecules stayed in their ON or OFF state for the duration of the experiment). Accordingly, continuous high intensity (100%) 660 nm light prevented calcium influx when PhyBt(660) was added to the GFP-PIF^S^-TCR cells ([Figure 6B](#fig6){ref-type="fig"}, orange line). After 390 s the constant 660 nm illumination was stopped, so that the PhyB molecules that were in the ON state at this moment were trapped in this state. This allowed them to bind long enough to the TCR and to induce a strong calcium response ([Figure 6B](#fig6){ref-type="fig"}). This experiment also demonstrates that the constant high intensity 660 nm illumination did not harm the cells.

![The half-life of the ON state of PhyB determines TCR signaling.\
(**A**) Schematics of the different PhyB conversions under 660 nm and 740 nm light. In the dark the PhyB states do not change in the timescales relevant for this work. (**B**) Calcium influx was measured as in [Figure 5](#fig5){ref-type="fig"}. GFP-PIF^S^-TCR cells were constantly illuminated with 100% intensity 660 nm light (orange line). After 150 s PhyBt(660) was added (arrow) and after 390 s the light was switched off. As controls, PhyBt(660) (blue line) or PhyBt(740) (red line) was added to the cells in the dark. The bars represent the illumination procedure during the measurement (grey = dark, orange = 660 nm light). (**C**) 20 nM PhyBt(660) was added (arrow) after 90 s to GFP-PIF^S^-TCR cells continuously illuminated with 660 nm light of the depicted intensities. Results in (**B**) and (**C**) show one experiment of n \> 3. (**D**) Quantification of experiments done as in (**C**) with the indicated PhyBt concentrations. Duplicates are shown with connecting lines going through the mean.\
10.7554/eLife.42475.011Figure 6---source data 1.Calcium influx quantification data at steady-state.](elife-42475-fig6){#fig6}

The intensity of 660 nm light determines the half-life of both PhyB states and consequently the switch rates between the ON and the OFF state. However, the 80:20 molar ratio of PhyB ON to OFF molecules at photoequilibrium is largely independent of the light intensity ([Figure 6A](#fig6){ref-type="fig"}) ([@bib10]; [@bib69]). Lowering the 660 nm intensity increases the half-life of PhyB ON without altering its concentration, and hence may allow PhyBt to bind for longer durations to the GFP-PIF^S^-TCR. Indeed, at 4% and 2% constant 660 nm intensity, calcium influx was evoked ([Figure 6C](#fig6){ref-type="fig"}). These percentage values refer to the maximum intensity of 100% that was determined by the light source we used. We observed a threshold of the PhyB ON half-life in inducing a calcium response that was largely independent of the PhyBt concentration, a crucial property of TCR ligand discrimination ([@bib54]) ([Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). This threshold half-life was at 3% 660 nm intensity. Thus, we were able to control TCR signaling by changing the intensity of continuous 660 nm light, suggesting that the duration of the ligand-TCR interaction controls calcium signaling.

Next, we tested whether very fast kinetics can terminate an ongoing TCR signal. GFP-PIF^S^-TCR cells were stimulated with PhyBt(660) in the dark, inducing a strong calcium response ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). During this response the long binding events were changed to fast binding events by illuminating with high intensity continuous 660 nm light (32% and 16%). As expected, the calcium signal was stopped, similar as when using 740 nm light ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"} and [Figure 5D](#fig5){ref-type="fig"}). The calcium response was not stopped when low intensity continuous 660 nm light (2% and 4%) was used, where the half-life of binding is still long. The threshold half-life of the PhyBt-GFP-PIF^S^-TCR interaction to maintain the calcium response was again at 3% 660 nm intensity ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}).

In conclusion, we engineered the opto-ligand-TCR system, in which one single ligand-TCR pair explores a wide range of different binding half-lives when changing the intensity of red light and in which other parameters of the interaction remain constant, because we have not mutated the binding interface.

A mathematical model describing KPR in the opto-ligand-TCR system {#s2-5}
-----------------------------------------------------------------

Next, we developed a mathematical model and confronted it with the experimental data, to obtain quantitative insight into how the half-life of the PhyB ON-TCR complex determines TCR signaling. The model comprises the PhyB ON-OFF cycle, binding of PhyBt to the TCR, and potentially KPR ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplements 1](#fig7s1){ref-type="fig"} and [2](#fig7s2){ref-type="fig"} and Appendix 2). In the absence of KPR, the activity of each component in the signaling network depends only on the activity of its immediate upstream component(s), making TCR occupancy the ultimate source of ligand discrimination. In contrast, KPR assumes that the first signaling steps at the receptor in addition depend on the half-life of the ligand-TCR complex, while only the more downstream components respond exclusively to the activity of their immediate upstream component(s). We refer to the time required to complete the first half-life-dependent signaling steps as KPR duration or KPR time, *τ*~KPR~.

![T cells exploit a kinetic proofreading mechanism.\
(**A**) The PhyB ON-OFF cycle, binding of PhyB ON to the TCR and kinetic proofreading (KPR) were combined into one model. (**B**) In this model the effective off-rate is a linear function, and (**C**) the effective affinity is the reciprocal of a linear function, of the 660 nm light intensity. (**D**) A likelihood ratio test (null hypothesis: τ~KPR~ = 0, i.e., no KPR; alternative hypothesis: τ~KPR~ \> 0) strongly supports the existence of a KPR mechanism. (**E**) The amount of PhyBt bound to the GFP-PIF^S^-TCR cells and (**F**) calcium influx at different continuous 660 nm light intensities (from [Figure 6D](#fig6){ref-type="fig"}) and different PhyBt concentrations are plotted. The line and shaded area represent the fit and the estimated uncertainties of the KPR model. The data points represent the mean ±SEM of 6--9 replicates in (**E**), or individual data points of two experiments in (**F**).](elife-42475-fig7){#fig7}

We used a soluble TCR ligand for which - in case of antibodies or pMHC - it was shown that bivalent binding is required to activate the TCR ([@bib14]; [@bib17]; [@bib38]; [@bib55]), and this most likely was also the case for our opto-ligand-TCR system ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Thus, the KPR duration in our system is the time from bivalent binding to the completion of the biochemical signaling steps ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

KPR requires the bivalently bound PhyBt-TCR complex to exist for at least the KPR time, in order to generate a signal that then leads to a calcium response more downstream ([@bib6]; [@bib23]; [@bib44]; [@bib54]) ([Figure 7A](#fig7){ref-type="fig"}, bivalent binding is shown in [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Thus, the time delay between bivalent ligand binding and calcium influx consists of the KPR duration plus the extra time beyond KPR required for the additional signaling steps until opening of the calcium channels. The half-life of the bivalent PhyBt-TCR complex is determined by the sum of the light-independent off-rate of PhyB ON from the TCR, *k*~off~, and the light intensity-dependent rate *k*~i~ with which PhyB molecules return to the OFF state, detaching from the TCR ([Figure 7B](#fig7){ref-type="fig"}).

In support of the model ([Figure 7A](#fig7){ref-type="fig"}), we experimentally demonstrated that the rate of converting PhyB from ON to OFF is the same for free PhyB and PIF-bound PhyB ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). These data imply that PhyB molecules also convert to OFF while being bound to PIF and thereby the PhyB-PIF interaction is lost. Hence, the effective off-rate and binding affinity of PhyB ON to the TCR are also light-dependent ([Figure 7B,C](#fig7){ref-type="fig"}). Taken together, the model predicts that the amount of TCR-bound PhyB decreases with increasing light intensity, which we confirmed experimentally ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}). Importantly, the change of PhyB ON affinity is a straightforward consequence of the light-controlled PhyB ON half-life (this contrasts with mutated pMHC ligands ([@bib6]; [@bib20]; [@bib23]; [@bib32]; [@bib44]), where affinity changes can be brought about by changes in both on- and off-rates, and potentially other parameters such as orientation of binding ([@bib2])).

Experimental data and modeling demonstrate that KPR takes place {#s2-6}
---------------------------------------------------------------

Although we intended to only change the ligand-TCR half-life with light, we also changed the affinity, due to the intrinsic relationship between off-rate and affinity. Hence, the intensity of 660 nm light regulates both the half-life of PhyB ON and the amount of bound PhyBt. To disentangle the half-life from the amount of ligand-bound TCRs, we asked whether calcium signaling was directly sensitive to the PhyB ON half-life through KPR or solely responded to the level of TCR occupancy with PhyB ON (absence of KPR). We fitted both mathematical models, the one with and the one without KPR, to the PhyBt binding and calcium signaling data together. Only the model with KPR yielded a satisfactory fit, and a likelihood ratio test, with the absence of KPR being the null hypothesis and the presence of KPR being the alternative hypothesis, showed highly significant support for the KPR model (p\<10^−6^, [Figure 7D,E,F](#fig7){ref-type="fig"} and [Figure 7---figure supplement 5](#fig7s5){ref-type="fig"}). Taken together, these findings strongly support the existence of KPR at the TCR.

The KPR time in Jurkat cells using the opto-ligand-TCR is 8 s {#s2-7}
-------------------------------------------------------------

The steady-state data ([Figure 7E,F](#fig7){ref-type="fig"}) prevented the model to deduce the KPR time *τ*~KPR~, yielding only the product *τ*~KPR~ · *k*~off~. To overcome this limitation, we determined the conversion kinetics of PhyB in our experimental system by illuminating PhyBt OFF with short light pulses of 660 nm light and subsequently switching to darkness. This protocol traps the ligands in the ON state, which we quantified through the resulting calcium signal ([Figure 8A](#fig8){ref-type="fig"} and Appendix 2). The resulting kinetics of switching PhyB to the ON state was highly consistent across different light intensities and PhyBt concentrations ([Figure 8B](#fig8){ref-type="fig"}) and were described well by the mathematical model. Importantly, combining the steady-state data ([Figure 7E,F](#fig7){ref-type="fig"}) and the kinetic data ([Figure 8B](#fig8){ref-type="fig"}) was sufficiently informative to identify all five parameters of the model ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Utilizing the kinetic data, we determined the half-life of the PhyB ON-TCR complex, ln2 /(*k*~off~ +*k*~i~), which varied from 40 s to 2 s over the range of light intensities used ([Figure 8C](#fig8){ref-type="fig"}). We determined the threshold half-life of the bivalent PhyBt-TCR interaction, i.e. the proofreading duration *τ*~KPR~, to be 8 s (95% CI: 3 s, 19 s) ([Figure 8D](#fig8){ref-type="fig"}). Thus, for a threshold half-life of bivalent binding of PhyBt to the TCR complex of 8 s, signaling from the active TCR is half-maximal. Furthermore, our results largely exclude the possibility of fast rebinding events, which would have effectively prolonged the half-life of the PhyB ON-TCR complex sensed by a KPR mechanism ([@bib5]; [@bib29]) (Appendix 2).

![Kinetic proofreading at the TCR occurs with a half-life of 8 s.\
(**A**) 20 nM PhyBt(740) was added to GFP-PIF^S^-TCR cells and a 660 nm pulse of 100% intensity was given for the indicated durations. The calcium influx was quantified over time, indicating that longer pulse durations switch more PhyB OFF molecules to the ON state. Stimuli addition is marked by an arrow and the illumination procedure by a bar above the graph (grey = dark, orange = 660 nm). (**B**) Experiment as in (A) were performed using 6.3 nM or 20 nM PhyBt and 32% or 100% intensity 660 nm light. The data is shown together with the fit and estimated SD. Results in (A) and (B) show one experiment of n \> 3. (**C**) The estimated half-lives of the PhyB-TCR complex in dependence on the light intensity. (**D**) The profile likelihood of the KPR time shows that the 95% confidence interval (CI) ranges from 3 s to 19 s, while the best-fit value is 8 s.\
10.7554/eLife.42475.021Figure 8---source data 1.Calcium influx quantification data for different 660 nm pulse durations and PhyBt concentrations.](elife-42475-fig8){#fig8}

Discussion {#s3}
==========

In this study, we engineered a tailor-made optogenetic system, the opto-ligand-TCR, to control a ligand-receptor interaction by light, allowing us to overcome current experimental limitations. In fact, one single ligand-TCR pair (the PhyBt - GFP-PIF^S^-TCR pair) can explore a wide range of different binding half-lives when changing the intensity of 660 nm light. Indeed, our approach exploits the remarkable, but in optogenetics so far unexplored, biophysical property of PhyB that the intensity of 660 nm light determines the half-life of the PhyB ON state ([@bib10]; [@bib64]; [@bib69]) and thus the half-life of the ligand-TCR interaction. Other parameters of the interaction remain constant, because the binding interface is always the same under the different light conditions. Together with a mathematical model, our data show that KPR can explain ligand discrimination by T cells.

Furthermore, using the PhyB-PIF pair enables switching ON and OFF ligand binding (short pulse of 660 and 740 nm light, respectively) in less than a second ([Figure 8B](#fig8){ref-type="fig"}). Importantly, we show that 740 nm light actively disrupts an existing PhyB-PIF interaction, rather than preventing rebinding. Both features, the light-induced switch between both states and the light intensity-dependent change in the binding dynamics, is only found with phytochromes and not with other optogenetic or synthetic systems ([@bib42]; [@bib69]).

Previously, light has been used to induce ligand-binding to the TCR. A lysine side chain of the peptide presented by MHC was modified with a light-sensitive caging group ([@bib34]). This modified pMHC could not bind to the TCR until a short UV light pulse (microsecond range) removed the caging group. Subsequently, pMHC could bind and stimulate signaling. In contrast to the opto-ligand-TCR system, this approach is not reversible, thus not allowing varying the half-life. Another approach is presented in the accompanying paper by Tischer and Weiner ([@bib78]). It uses a blue-light responsive optogenetic tool, namely the LOVTRAP system ([@bib83]). In this case LOV2 binds to a chimeric antigen receptor and the blue light intensity controls the duration of binding. In analogy to our data, they show that the half-life of ligand binding controlled T cell activation.

The opto-ligand-TCR system was not only able to provoke calcium and Erk MAP kinase signaling (not shown), but also led to the stimulation of the T cell as measured by the upregulation of the activation marker CD69. This is in line with systems where other binding domains were fused to the TCR (single chain Fv and DNA, ([@bib55]; [@bib68]; [@bib76]), indicating that the TCR can be fully stimulated in synthetic settings and not only by pMHC. This feature is also exploited in chimeric antigen receptors used for cancer immunotherapy ([@bib46]; [@bib66]).

Our opto-ligand-TCR system allowed us to show that T cells discriminate between ligands due to differences in the ligand-TCR half-lives ([Figure 8](#fig8){ref-type="fig"}), consistent with KPR models ([@bib6]; [@bib23]; [@bib44]; [@bib54]). Using the identical ligand-TCR pair for the different half-lives excludes differences in binding geometry ([@bib2]), forces ([@bib41]; [@bib48]) or conformational changes ([@bib28]) as discriminatory parameters in this setup. Furthermore, we measured total binding, the binding kinetics and the activation readout in the same experimental system. Thus, all parameters for the mathematical model are derived using identical conditions. This is often different when using pMHC and variants thereof as ligands for the TCR: the binding parameters are derived by surface plasmon resonance at 25°C using recombinant parts of the proteins (ectodomains of pMHC and only the immunoglobulin domains of the TCRα and TCRβ subunits) and the activation assays are done with native, membrane or surface bound proteins at 37°C ([@bib5]; [@bib25]; [@bib29]; [@bib32]; [@bib43]). Thus, it is often unclear how well these different biological setups can be compared and compiled into one model.

Besides our and other studies on the correlation of binding parameters with the biological activity of the ligands, differential CD3ζ phosphorylation is another hint for KPR. CD3ζ is a signaling subunit of the TCR that can be partially or fully phosphorylated. Low affinity pMHC, which are non-stimulatory, lead to partial phosphorylation, whereas high affinity pMHC, which are stimulatory, lead to full phosphorylation of CD3ζ ([@bib50]; [@bib80]). This is consistent with the idea that the low affinity ligands only bind shortly, not allowing all phosphorylation steps to be completed and high affinity ligands bind long enough to complete all phosphorylations. Indeed, increasing the concentration of the low affinity binders did not lead to full CD3ζ phosphorylation ([@bib51]), being consistent with KPR.

Interestingly, changing the half-life of PhyB ON and thus the lifetime of the ligand-TCR interaction also altered the amount of bound receptors, and with the help of the mathematical model we could show that the half-life was the decisive parameter for the magnitude of T cell stimulation as measured by calcium influx. We calculated the threshold half-life above which TCR stimulation occurs, i.e., the KPR duration, to be 8 s. For soluble TCR ligands, as we have used here, it has been shown that bivalent binding is required to trigger the TCR ([@bib14]; [@bib17]; [@bib38]), possibly due to both a lack of clustering and stabilization of conformational changes of the TCR ([@bib55]; [@bib67]; [@bib74]). Indeed, also in our case PhyB monomers did not activate the TCR whereas PhyB tetramers (PhyBt) did. Thus, the PhyBt ligands needed to bind for at least 8 s bivalently, in order to stimulate calcium influx that itself occurred later. Of note, the KPR duration is not identical to the time delay between ligand binding and calcium influx or other downstream events ([Figure 9](#fig9){ref-type="fig"}). A time delay is a prerequisite for KPR, but does not necessarily indicate that KPR takes place.

![Kinetic proofreading determines T cell activation.\
Ligands that bind shorter than the KPR time of 8 s (half-life of binding) fail to induce efficient TCR signaling. Ligands that bind longer allow the completion of several biochemical steps (white arrows) that result in an activatory signal by the TCR. This signal provokes further signaling (grey arrows) that ultimately leads to T cell activation.](elife-42475-fig9){#fig9}

In line with our 8 s KPR time, the accompanying paper by Tischer and Weiner found a KPR time of approximately 7 s ([@bib78]). This study also used Jurkat cells, but a different optogenetic system, a different activation readout and a chimeric antigen receptor instead of a TCR. Thus, independent of the readout and exact design of the optogenetic system Jurkat cells have a TCR/-chimeric antigen receptor based KPR time of 7--8 s. Most other studies have calculated a KPR time of between 1--5 s ([@bib5]; [@bib6]; [@bib20]; [@bib29]; [@bib32]; [@bib39]) and the time delay between ligand binding and calcium influx was 7 s in one study ([@bib34]). In contrast to those studies, our and the Tischer/Weiner systems lack the co-receptor CD4 and CD8 that have been shown to increase the speed of signaling, most likely by efficiently recruiting the kinase Lck to the TCR ([@bib8]; [@bib32]; [@bib81]). Differences in the cellular background (primary murine T cells versus the human T cell line Jurkat) might also contribute to differences in the KPR time, e.g., if the concentration of kinases or phosphatases was different ([@bib6]).

The half-life of the interaction is a population average over many binding events. Thus, it might be that individual binding events longer than the threshold half-life (8 s in our case) are the ones that triggered T cell activation, as suggested recently ([@bib47]). The opto-ligand-TCR system is well suited to precisely control the exact binding time (and not the average half-life) by using 740 nm light to break the ligand-TCR interaction.

An aspect to consider in KPR is a potential contribution of fast rebinding of ligands to TCRs ([@bib5]; [@bib29]). When the on-rate of multivalent binding of the pMHC-TCR interaction is sufficiently fast, dissociated TCRs are rebound before KPR modifications are removed ([@bib5]; [@bib29]), effectively prolonging the half-life of the TCR-ligand interaction. However, the on-rate in our opto-ligand-TCR system seems to be too slow to significantly contribute to this effect (Appendix 2).

Our approach, including the designed PIF^S^ mutant, could be a blueprint to study other ligand-receptor pairs and to understand how the kinetics of protein-protein interactions governs the activity of these binding events in diverse biological systems. Further, the opto-ligand-receptor approach is also well suited to locally induce signaling by focusing the light beam to the region of interest.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\            Designation                    Source or reference         Identifiers        Additional information
  (species) or resource                                                                                  
  ------------------------ ------------------------------ --------------------------- ------------------ ------------------------------
  Genetic reagent\         moxGFP                         PMID: 26158227                                 Erik Snapp (Albert Einstein\
  (Aequorea victoria)                                                                                    College of Medicine),\
                                                                                                         Addgene plasmid \# 68070

  Genetic reagent\         PIF6                           PMID: 29603429                                 
  (Arabidopsis thaliana)                                                                                 

  Genetic reagent\         HA1.7 TCRβ                     PMID: 17188005                                 
  (Homo sapiens)                                                                                         

  Genetic reagent\         scFv                           PMID: 17188005                                 
  (Mus musculus)                                                                                         

  Cell line\               Jurkat                         PMID: 15057788                                 Arthur Weiss\
  (Homo sapiens)                                                                                         (HHMI, UCSF)

  Cell line\               Jurkat scFv-TCRβ               this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         scFv-TCRβ

  Cell line\               Jurkat PIF(wt)-TCRβ            this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         PIF(wt)-TCRβ

  Cell line\               Jurkat PIF(Q)-TCRβ             this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         PIF(Q)-TCRβ

  Cell line\               Jurkat PIF(A)-TCRβ             this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         PIF(A)-TCRβ

  Cell line\               Jurkat PIF(SS)-TCRβ            this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         PIF(SS)-TCRβ

  Cell line\               Jurkat PIF(SSQ)-TCRβ           this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         PIF(SSQ)-TCRβ

  Cell line\               Jurkat PIF(SSA)-TCRβ;\         this paper                                     Jurkat expressing\
  (Homo sapiens)           Jurkat PIF^S^-TCRβ                                                            PIF(SSA)-TCRβ

  Cell line\               Jurkat GFP-F1-PIF^S^-TCRβ      this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         GFP-F1-PIF^S^-TCRβ

  Cell line\               Jurkat GFP-F2-PIF^S^-TCRβ      this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         GFP-F2-PIF^S^-TCRβ

  Cell line\               Jurkat GFP-F3-PIF^S^-TCRβ      this paper                                     Jurkat expressing\
  (Homo sapiens)                                                                                         GFP-F3-PIF^S^-TCRβ

  Cell line\               Jurkat GFP-noF-PIF^S^-TCRβ;\   this paper                                     Jurkat expressing\
  (H. sapiens)             Jurkat GFP-PIF^S^-TCRβ                                                        GFP-noF-PIF^S^-TCRβ

  Antibody                 anti-Vβ3 Jovi3                 Ancell Cat\# 102-020        \-                 5 µg/ml

  Antibody                 biotin-conjugated\             Rockland Cat\#\             RRID:AB_218204     5 µg/ml
                           anti-GFP                       600-106-215                                    

  Antibody                 APC-conjugated\                Thermo Fisher\              RRID:AB_10372807   1:200
                           anti-CD69                      Cat\# MHCD6905                                 

  Antibody                 APC-conjugated\                SouthernBiotech\            \-                 1:200
                           anti-mouse                     Cat\# 1031-11L                                 

  Recombinant\             PhyB~1-651~-Aviag-His~6~;\     PMID: 27884151                                 
  DNA reagent              pMH17                                                                         

  Recombinant\             p171                           PMID: 18832155                                 Lars-Oliver Essen\
  DNA reagent                                                                                            (University Marburg)

  Recombinant\             PIF(wt)-TCRβ;\                 this paper                                     see Table S1
  DNA reagent              pOSY015                                                                       

  Recombinant\             PIF(Q)-TCRβ;\                  this paper                                     see Table S1
  DNA reagent              pOSY016                                                                       

  Recombinant\             PIF(A)-TCRβ;\                  this paper                                     see Table S1
  DNA reagent              pOSY017                                                                       

  Recombinant\             scFv-TCRβ;\                    this paper                                     see Table S1
  DNA reagent              pOSY019                                                                       

  Recombinant\             PIF(SS)-TCRβ;\                 this paper                                     see Table S1
  DNA reagent              pOSY026                                                                       

  Recombinant\             PIF(SSQ)-TCRβ;\                this paper                                     see Table S1
  DNA reagent              pOSY027                                                                       

  Recombinant\             PIF(SSA)-TCRβ;\                this paper                                     see Table S1
  DNA reagent              PIF^S^-TCRβ;\                                                                 
                           pOSY028                                                                       

  Recombinant\             MBP-PIF(wt);\                  this paper                                     see Table S1
  DNA reagent              pOSY061                                                                       

  Recombinant\             MBP-PIF(Q);\                   this paper                                     see Table S1
  DNA reagent              pOSY062                                                                       

  Recombinant\             MBP-PIF(A);\                   this paper                                     see Table S1
  DNA reagent              pOSY063                                                                       

  Recombinant\             MBP-PIF(SS);\                  this paper                                     see Table S1
  DNA reagent              pOSY064                                                                       

  Recombinant\             MBP-PIF(SSQ);\                 this paper                                     see Table S1
  DNA reagent              pOSY065                                                                       

  Recombinant\             MBP-PIF(SSA);\                 this paper                                     see Table S1
  DNA reagent              pOSY066                                                                       

  Recombinant\             GFP-F1-PIF^S^-TCRβ;\           this paper                                     see Table S1
  DNA reagent              pOSY073                                                                       

  Recombinant\             GFP-F2-PIF^S^-TCRβ;\           this paper                                     see Table S1
  DNA reagent              pOSY074                                                                       

  Recombinant\             GFP-F3-PIF^S^-TCRβ;\           this paper                                     see Table S1
  DNA reagent              pOSY075                                                                       

  Recombinant\             GFP-noF-PIF^S^-TCRβ;\          this paper                                     see Table S1
  DNA reagent              GFP-PIF^S^-TCRβ;\                                                             
                           pOSY076                                                                       

  Peptide,\                PE-conjugated\                 Thermo Fisher Cat\# S866    \-                 
  recombinant\             streptavidin                                                                  
  protein                                                                                                

  Peptide,\                DyLight650-conjugated\         Thermo Fisher Cat\# 84547   \-                 
  recombinant\             streptavidin                                                                  
  protein                                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------

Molecular cloning {#s4-1}
-----------------

All plasmids generated in this study were created using standard molecular cloning techniques like polymerase chain reaction, restriction enzyme digestion and ligation or Gibson assembly ([@bib27]). The plasmids are listed in Table S1 together with the corresponding coded protein, a brief description of the used components and the cloning strategy. The primers used as described in [Supplementary file 1](#supp1){ref-type="supplementary-material"} are summarized in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Plasmid maps and nucleotide sequences in GeneBank format are available as supplementary information. Plasmid maps were generated with Geneious 6.1.8 (<https://www.geneious.com>). The integrity of each plasmid was verified by restriction enzyme digestion and Sanger sequencing. The plasmid containing moxGFP was a gift from Erik Snapp (Addgene plasmid \# 68070) ([@bib18]).

Protein production and purification {#s4-2}
-----------------------------------

The production of PhyB~1-651~-Aviag-His~6~ was performed similarly as described before ([@bib69]). Briefly, the PhyB-coding plasmid pMH17 was co-transformed into *E. coli* BL21(DE3) with plasmid p171 ([@bib65]), which codes for the *Synechocystis* enzymes heme oxygenase and phycocyanobilin synthase, necessary for phycocyanobilin production. Co-transformed cells were selected with 100 μg/ml ampicillin and 40 μg/ml kanamycin. Bacterial cultures were grown at 30°C in lysogeny broth until OD~600~ reached 0.6, then expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 0.4% (w/v) arabinose in the presence of 50 μM biotin. Protein production was sustained for 20 hr at 18°C in the dark. Following centrifugation of the bacteria for 8 min at 6500 *g*, the cells were resuspended in lysis buffer (50 mM HEPES, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 20 mM imidazole, pH 7.4) and disrupted using a French Press (APV 2000, APV Manufacturing) at 1,000 bar. The lysate was cleared from debris by centrifuging twice at 30,000 *g* at 4°C for 30 min. The cleared lysate was loaded onto a Ni-NTA Superflow cartridge (Qiagen) using an Äkta Explorer chromatography system (GE Healthcare). After washing with 30 column volumes lysis buffer, purified PhyB~1-651~-Avitag-His~6~ was eluted with 10 column volumes elution buffer (50 mM HEPES, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 500 mM imidazole, pH 7.4). The eluate fractions containing the purified proteins were pooled and the buffer was exchanged to PBS (phosphate-buffered saline, Sigma-Aldrich) containing 0.5 mM TCEP and 10% glycerol using a HiPrep 26/10 desalting column (GE Healthcare).

The expression and purification of the different MBP-PIF6~1-100~ proteins was performed analogous to PhyB, with the difference that the plasmids pOSY061 until pOSY066 were transformed individually without p171, protein expression was induced using only IPTG and no biotin was added to the medium.

PhyB tetramers (PhyBt) were formed by mixing Ni-NTA column-purified PhyB~1-651~-Avitag-His~6~ in a 10:1 molar ratio with PE- or DyLight650-conjugated streptavidin (Thermo Fisher) and incubating the mixture for 2 hr at room temperature in the dark. The formed PhyB tetramers were separated from the excess of PhyB monomers by size-exclusion chromatography on a HiLoad Superdex 200 pg column (GE Healthcare) using PBS with 0.5 mM TCEP as running buffer.

Analytical size-exclusion chromatography {#s4-3}
----------------------------------------

To test the interaction of PhyB and MBP-PIF, PhyB was illuminated with saturating amounts of 660 or 740 nm light and MBP-PIF was added as depicted. Following incubation for 1 hr at room temperature in the dark, the samples were separated by size-exclusion chromatography on a Superdex 200 10/300 GL column (GE Healthcare) using PBS with 0.5 mM TCEP as running buffer.

Cell line generation and cultivation {#s4-4}
------------------------------------

Jurkat E6.1 and derived cell lines were cultivated in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin (all Thermo Fisher) at 37°C in a humidified atmosphere of 5% CO~2~. HEK 293 T cells were cultured in DMEM (Thermo Fisher) supplemented as the RPMI medium at 37°C in a humidified atmosphere of 7.5% CO~2~.

For the generation of Jurkat-based cell lines stably expressing the chimeric TCRβ chains, we used lentiviral transduction as described earlier ([@bib24]). Briefly, HEK 293 T cells were transfected with the lentiviral packaging plasmid pCMV dR8.74, the envelope plasmid pMD2 vsvG (both kind gifts from Didier Trono) and the respective transfer plasmid by calcium phosphate precipitation. 6 hr post-transfection the medium was replaced and lentiviral particles were produced by the HEK 293 T cells for 48 hr. Lentiviral particle-containing HEK 293T supernatant was harvested, filtered through a 0.45 µm syringe filter and concentrated by overnight centrifugation at 3,000 *g* at 4°C through a 20% (w/v in PBS) sucrose cushion. After discarding the supernatant, the viral particles were resuspended in medium using 1/100^th^ of the harvested volume. Jurkat cells were transduced with different dilutions of concentrated lentiviral particles and 48 hr after transduction, surface expression and cell viability were analyzed by flow cytometry.

The identity of the Jurkat cells was confirmed by the binding to the antibody C305 that only binds to the TCR expressed on Jurkat cells ([@bib84]). The identity of the HEK 293 T cells was not confirmed. All cells were routinely tested for mycoplasma and devoid of contamination.

Cell surface staining for flow cytometry {#s4-5}
----------------------------------------

Cells were stained for surface proteins according to standard protocols. Briefly, cells were washed once with washing buffer (PBS supplemented with 1% FBS), then incubated for 30 min at 4°C in a diluted solution of the labeling antibody as depicted in the key resources table. Finally, the cells were washed twice as before and analyzed on a MACSQuant X flow cytometer (Miltenyi). The labeling reagents used in this study were anti-Vβ3 Jovi3 (Ancell), biotin-conjugated anti-GFP (Rockland Immunochemicals), APC-conjugated anti-CD69 (Thermo Fisher), APC-conjugated anti-mouse (Thermo Fisher) and PE-conjugated streptavidin (Thermo Fisher).

Light-dependent PhyBt binding to the cell surface {#s4-6}
-------------------------------------------------

Binding of PhyBt to the different cells lines was performed analogous to the cell surface staining with antibodies, but instead of labeled antibodies 100 nM pre-illuminated Phycoerythrin (PE)-labeled PhyBt(660) or PhyBt(740) were added to the cells and incubated for 30 min at 4°C in the dark. Subsequent washing steps and the measurement at the flow cytometer were executed under green light.

To evaluate the amount of surface bound PhyBt under constant illumination with varying intensities of 660 nm light, different concentrations of PhyBt(660) were added to GFP-PIF^S^-TCR cells under illumination conditions as depicted and incubated for 90 s at 37°C. Subsequently, the cells were transferred to a ten-fold excess of ice-cold washing buffer, immediately centrifuged for 10 s under green light and the supernatant aspirated. After a second washing step, surface-bound PhyBt was quantified by flow cytometry. Unspecific binding was accounted for and subtracted from each sample by adding ten-fold diluted amounts of PhyBt(660) to control samples that were treated with washing buffer during the 90 s incubation step.

Calcium influx measurement {#s4-7}
--------------------------

Five million cells were centrifuged for 5 min at 300 *g* and the medium was discarded. The cell pellet was resuspended in 1 ml stimulation medium (RPMI 1640 medium supplemented with 1% FBS, 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin) with 0.1% (v/v) pluronic F-127 and 4 µM Indo-1 AM (all Thermo Fisher) and incubated in the dark for 30 min at 37°C. The stained cells were washed and kept on ice in the dark until the measurement. For calcium influx, cells were diluted 1:20 with pre-warmed stimulation medium and maintained at 37°C during the event collection on a MACSQuant X flow cytometer. After fluorescence baseline acquisition, stimuli were added or activated by illumination as depicted. If not indicated otherwise PhyBt were added to a final concentration of 20 nM.

For the graphs showing the percent of responding cells, the events above the 90^th^ percentile during baseline acquisition were quantified using FlowJo 9 (FlowJo LLC). To calculate the calcium influx values (a.u.), average Indo-1 ratio values after stimuli addition (250--400 s) minus baseline values (30--60 s) were normalized for each experiment using an internal control of 20 nM PhyBt(660) in the dark.

CD69 upregulation {#s4-8}
-----------------

200,000 Jurkat or GFP-PIF^S^-TCR cells were seeded per well in a 96-well flat-bottom plate in 100 µl stimulation medium and incubated for 1 hr in the cultivating incubator. Meanwhile, streptavidin sepharose beads (GE Healthcare) were washed with PBS and then incubated with 5 µg purified PhyB per µl beads (diluted in PBS) at 37°C for 30 min. The beads were washed twice with PBS and resuspended in stimulation medium at 2 µl beads per 100 µl medium. The diluted beads were illuminated as described, 100 µl bead suspension added per well to the cells and the cells stimulated for 6 hr in the incubator. Following the incubation, surface expression of CD69 was analyzed by flow cytometry as described above.

Determination of PhyB conversion rates {#s4-9}
--------------------------------------

50 µg purified PhyB(660) or PhyB(740) was mixed with a 6-fold excess of MBP-PIF(wt) or an equal volume of buffer (PBS with 0.5 mM TCEP) and incubated for 60 min at room temperature. Each protein mixture was transferred to a quartz cuvette, a blank measurement was taken and under constant illumination with 70 µmol m^−2^ s^−1^ 660 or 740 nm light difference absorbance spectra were acquired every 10 s using a HR4000 spectrometer in combination with a DT-Mini-2-GS light source (Ocean Optics). We quantified the conformational change of PhyB by subtracting the minimum absorbance value from the maximum value and plotted this ΔΔA value against the time of illumination (not shown). From the resulting curves, we calculated the photoconversion rates by first order association kinetics nonlinear regression using the software Prism 6 (GraphPad Software). Differences in the conversion rates with or without MBP-PIF were tested by two-way ANOVA using Prism 6.

Illumination devices {#s4-10}
--------------------

For the different experiments performed in this study, we used two types of illumination devices. One device was built as a closed box with an array of red (Osram, LH W5AM, Mouser Electronics) and far-red (LZ4-00R308, LED Engin) light-emitting diodes (LEDs) at the top, resulting in a planar light source. Ventilated openings in the box in combination with light traps allowed gas exchange for the use of the device in an incubator. This illumination box was used for all pre-illumination steps, the CD69 upregulation experiments and PhyB conversion rate measurements.

The second device was built together with Opto Biolabs as a cylinder enclosing a reaction tube in the center. Surrounding the reaction tube, is a water-filled space, which is connected to a 37°C water bath to keep a physiological temperature. Further outside we placed rings of red (Super Bright Red, Kingbright Electronic Europe) and far-red (LED740 series, Roithner Lasertechnik) LEDs, pointing towards the reaction tube. An opaque outmost cylinder shields the sample from external light. The cylindrical illumination device was used for all calcium experiments and experiments under constant 660 nm illumination in combination with a MACSQuant X flow cytometer.

Repetition of experiments and data presentation {#s4-11}
-----------------------------------------------

In this study, all graphs derived from data of multiple experiments depict individual data points for less than three replicates and average values for three or more replicates. The uncertainties of these experiments are shown by the standard error of the mean (SEM). For graphs displaying representative experiments, 'n' in the legend defines the number of independent experiments that the depicted results were done.
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Data availability {#s7}
=================

All data that were analyzed with the mathematical model are provided in source data files.
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Glossary {#s8}
========

  ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PhyB                   Phytochrome B (photoreceptor of *Arabidopsis thaliana*), here only the first 651 amino acids are used, since this part is sufficient to bind PIF under 660 nm, but not under 740 nm light.
  PIF                    PhyB-interacting factor, here the first 100 aa of *A. thaliana* PIF6 are used, since they are sufficient to bind to PhyB.
  PIF^S^                 A mutant version of functional PIF developed in this study, that can move through the secretory pathway to the cell surface and remain in a functional conformation, i.e., it is still capable of binding PhyB.
  PhyBt                  Fluorescently labeled streptavidin-based tetramers of PhyB.
  PhyBt(660)             PhyBt pre-illuminated with 660 nm light, so that equilibrium is reached, in which 80% of the PhyB molecules are in their ON state
  PhyBt(740)             PhyBt pre-illuminated with 740 nm light, so that all PhyB molecules are in the OFF state
  PhyB ON                PhyB in the active conformation allowing binding to PIF with nanomolar affinity ([Figure 1](#fig1){ref-type="fig"}).
  PhyB OFF               PhyB in the inactive conformation, in which they cannot bind to PIF ([Figure 1](#fig1){ref-type="fig"}).
  ~τKPR~                 The KPR time or KPR duration. The half-life of the bivalent binding of the soluble ligand to the TCR needs to be at least this time to induce downstream, activatory signaling.
  moxGFP                 A GFP mutant (S30R, Y29N, C48S, F64L, S65T, C70S, Q80R, F99S, N105T, Y145F, M153T, V163A, I171V, A206K) that was optimized for the folding in the endoplasmic reticulum (ox) and that is expressed as a monomer (m).
  TCR                    T cell receptor. The receptor on T cells controlling T cell activation. It consists of the TCRα, TCRβ, CD3γ, CD3δ, CD3ε and ζ chains.
  PIF^S^-TCR             A preliminary non-functional TCR chimera, in which PIF^S^ is fused to the ectodomain of the TCRβ subunit.
  pMHC                   Peptide bound to Major Histocompatibility Complex constitutes the ligand for the TCR.
  GFP-PIF^S^-TCR         Our engineered TCR, in which the moxGFP and PIF^S^ are fused to the ectodomain of the TCRβ subunit.
  GFP-PIF^S^-TCR cells   Jurkat E6.1 T cells expressing the GFP-PIF^S^-TCR.
  ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.7554/eLife.42475.061

Mathematical model of TCR activation by the optogenetic ligand {#s9}
==============================================================

Dynamics of phytochrome B conversion {#s9-1}
------------------------------------

Phytochrome B (PhyB) exists in two conformations that can be reversibly interconverted by light with intensity-dependent rates *k~a~* and *k~i~* ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). The two conformations, which are referred to as PhyB ON respectively PhyB OFF, are distinguished by their ability to interact with PhyB interacting factor (PIF), as described in the next section. The rates of conformational conversion depend on the wavelength *λ* and the intensity *I* of the light. While the dependence on *λ* is very complicated, the rates depend linearly on the intensity ([@bib69]),$$k_{a}\left( {\lambda,I} \right) = c_{a}\left( \lambda \right) \bullet I + k_{r,a},$$$$k_{i}\left( {\lambda,I} \right) = c_{i}\left( \lambda \right) \bullet I + k_{r,i}.$$

The rates *k*~r,a~ and *k*~r,i~ describe thermal relaxation. However, the timescales used in the experiments are sufficiently small so that thermal relaxation can be neglected ([@bib69]), i.e., we set *k*~r,a~ = *k*~r,i~ = 0. This implies that the conversion between the ON state and the OFF state of PhyB freezes when the system is switched to darkness.

The equilibrium constant of PhyB conversion, *K*~L~, is given by the ratio of the conversion rates and depends only on the wavelength *λ*,$$K_{L}\left( \lambda \right) = {{k_{a}\left( {\lambda,I} \right)}/{k_{i}\left( {\lambda,I} \right)}} = {{c_{a}\left( \lambda \right)}/{c_{i}\left( \lambda \right)}}$$

Thus, an altered light intensity affects the rates of PhyB conversion but leaves the equilibrium constant unchanged. The conversion dynamics of PhyB at concentration *P*~tot~ is described by the law of mass action. The PhyB ON concentration (denoted by *P*~ON~) is given by the following ordinary differential equation ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}),$${{dP_{ON}}/{dt}} = k_{a}\left( I \right)\left( {P_{tot} - P_{ON}} \right) - k_{i}\left( I \right)P_{ON}.$$

To keep the notation simple, the dependence of the conversion rates on the wavelength *λ* has been dropped. The steady-state solution of [Equation (3)](#equ4){ref-type="disp-formula"} depends only on *λ* and the total PhyB concentration,$$P_{ON,eq}(\lambda) = \phi_{ON,eq}(\lambda)P_{tot}.$$

Here we introduced the equilibrium fraction of PhyB ON,$$\phi_{ON,eq}(\lambda) = K_{L}{(\lambda)}/(1 + K_{L}{(\lambda)}).$$

Thus changing the intensity at fixed wavelength does not impact the concentration of PhyB in the ON conformation.

The table below shows the equilibrium properties of PhyB conversion for the wavelengths used in the experiments ([@bib52]; [@bib69]).

  ----------- --------------- ---------
  $\lambda$   $\phi_{a,eq}$   $K_{L}$
  660nm       0.8             4
  740nm       0.01            0.01
  ----------- --------------- ---------

Binding model for PhyB interacting with GFP-PIF^S^-TCR {#s10}
======================================================

Monomeric PhyB binds the GFP-PIF^S^-TCR only in its active conformation (PhyB ON), while the inactive conformation does not interact with the GFP-PIF^S^-TCR (for simplicity the GFP-PIF^S^-TCR is called PIF-TCR in the remainder of the description of the mathematical model). We assume the total number of PhyB molecules to be in excess over the total number of PIF-TCR molecules to assure that the concentration of free PhyB is not depleted even if saturation is reached. We first consider the system kept in darkness (i.e., no conformational conversion of PhyB takes place) and PhyB ON at a fixed concentration *P*~ON~ ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}). The rate of change of the concentration of PhyB ON-PIF-TCR complexes, denoted by *y*~a~, is described by mass action kinetics,$${{dy_{a}}/{dt}} = k_{on} \bullet P_{ON} \bullet \left( {1 - y_{a}} \right) - k_{off} \bullet y_{a}.$$

The total amount of PIF-TCR on the surface of the T cell has been set to 1, i.e., [Equation (6)](#equ7){ref-type="disp-formula"} yields the amount of PhyB ON-PIF-TCR complexes as fraction of all PIF-TCRs. The steady-state solution *y*~a,eq~ is determined by the product of the binding affinity *K* = *k~on~*/*k~off~* and the concentration *P*~ON~,$$y_{a,eq}\left( P_{ON} \right) = {{K \bullet P_{ON}}/\left( {1 + K \bullet P_{ON}} \right)}.$$

We now consider the interaction of PhyB and PIF-TCR in the presence of light of wavelength *λ* and intensity *I*. If PhyB is in excess over PIF-TCR, the conversion dynamics of unbound PhyB is given by [Equation (3)](#equ4){ref-type="disp-formula"}. Next to the formation and dissociation of PhyB ON-PIF-TCR complexes, light absorption allows for the transition of PhyB ON to PhyB OFF when PhyB ON is in complex with PIF-TCR ([Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}, left). In this state the complex can either dissociate with off-rate *k'~off~* or PhyB converts to its ON conformation with rate *k~a~*. Importantly, the conversion rates of PhyB do not depend on whether PhyB is bound to PIF or not ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). The complex of PIF-TCR and PhyB OFF is very short-lived such that we assume *k'~off~* \>\>*k~a~*. In this limit the amount of PhyB OFF bound to PIF-TCR can be neglected ([Figure 7---figure supplement 2C](#fig7s2){ref-type="fig"}, right), and the dynamics of the formation of PhyB ON-PIF-TCR complexes is given by (as above, the total amount PIF-TCR on the T cell has been set to 1),$${{dy_{a}}/{dt}} = k_{on} \bullet P_{ON} \bullet \left( {1 - y_{a}} \right) - \left( {k_{off} + k_{i}\left( I \right)} \right) \bullet y_{a}.$$

This is the same dynamics as in darkness ([Equation 6](#equ7){ref-type="disp-formula"}) but dissociation is determined by an intensity-dependent effective off-rate,$$k_{off}^{*}\left( I \right) = k_{off} + k_{i}\left( I \right).$$

Thus, the PhyB-PIF system allows for tuning the off-rate in a linear manner by changing the light intensities ([Figure 7B](#fig7){ref-type="fig"}). Consequently, the affinity becomes intensity-dependent as well ([Figure 7C](#fig7){ref-type="fig"}),$$K^{*}\left( I \right) = {k_{on}/{k_{off}^{*}\left( I \right)}}.$$

The effective affinity equals the affinity in [Equation (7)](#equ8){ref-type="disp-formula"} if *I* = 0. It is the product of the effective affinity and the concentration of PhyB ON that determines the steady-state solution of [Equation (8)](#equ9){ref-type="disp-formula"},$$y_{a,eq}\left( {P_{ON},I} \right) = {{K^{*}\left( I \right) \bullet P_{ON}}/\left( {1 + K^{*}\left( I \right) \bullet P_{ON}} \right)}.$$

This is an important finding. Rather than just changing the rate of dissociation with light intensity, the amount of bound PIF-TCRs declines as well, which we confirmed experimentally ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}). It is therefore critical to take this effect readily into account.

Binding of oligomeric PhyB to PIF-TCR {#s11}
=====================================

To account for the oligomeric structure of the PhyB ligands used in the experiments, the concepts outlined above are generalized to account for multivalent binding. The principal difference between mono- and multivalent binding is found in the corresponding dose-response binding curves. While monovalent binding is a strictly increasing function of ligand concentration eventually reaching saturation, multivalent binding is characterized by a bell-shaped dose-response curve ([@bib60]). Indeed, our data are in line with this as the calcium response decreases at high concentrations ([Figure 6D](#fig6){ref-type="fig"}).

For simplicity we model the PhyB ligands as dimers, and we denote the concentration of PhyB oligomers with *j* subunits in the ON conformation by *P~j~* (*j* = 0, 1 and 2). At total concentration *P*~tot~ (= *P*~0~ + *P*~1~ + *P*~2~), the dynamics of PhyB conversion is given by$$dP_{1}/dt = 2\ k_{a}\left( I \right)\left( {P_{tot} - P_{1} - P_{2}} \right) - k_{i}\left( I \right)\ P_{1} - k_{a}\left( I \right)\ P_{1} + 2\ k_{i}\left( I \right)\ P_{2}\ ,$$$${{dP_{2}}/{dt}} = k_{a}\left( I \right)P_{1} - 2k_{i}\left( I \right)P_{2},$$$$P_{0} = P_{tot} - P_{1} - P_{2}.$$

The amount of PhyB ON subunits is *P*~ON~ = *P*~1~+2P~2~. The solution for the initial condition *P*~0~(0)=*P*~tot~, *P*~1~(0) = *P*~2~(0)=0 is given by$$$$

The steady-state solution is$$$$

This is accompanied by the binding dynamics. Next to the fraction of unbound PIF-TCR (=*T*), there are three possible binding states ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}): the PhyB ON subunit of *P*~1~ being in complex with PIF-TCR (= *y*~1,1~), one of the two PhyB ON subunits of *P*~2~ being in complex with PIF-TCR (= *y*~2,1~), and both PhyB ON subunits of *P*~2~ each in complex with a PIF-TCR (= *y*~2,2~). The corresponding rates of changes are described by mass action kinetics,$${{dy_{1,1}}/{dt}} = k_{on}P_{1} \bullet T - \left( {k_{off} + k_{i}\left( I \right)} \right)y_{1,1} - k_{a}\left( I \right)y_{1,1} + k_{i}\left( I \right)y_{2,1} + 2k_{i}\left( I \right)y_{2,2},$$$$dy_{2,1}/dt = 2\ k_{on}\ P_{2} \cdot T - \left( {k_{off} + k_{i}\left( I \right)} \right)\ y_{2,1} + \ k_{a}\left( I \right)\ y_{1,1} - k_{i}\left( I \right)\ y_{2,1} - q_{on}\ y_{2,1} \cdot T + 2\ q_{off}\ y_{2,2}\ ,$$$${{dy_{2,2}}/{dt}} = q_{on}y_{2,1} \bullet T - 2\left( {q_{off} + k_{i}\left( I \right)} \right)y_{2,2},$$$$1 = T + y_{1,1} + y_{2,1} + 2y_{2,2}.$$

The last equation describes the conservation of total PIF-TCR, which, as above, we have set to 1. As a consequence, the binding rate of receptor cross-linking, i.e., PhyB tetramers binding bivalently to two TCRs, *q*~on~ assumes the unit of an inverse time, making the cross-linking affinity *Q* = *q*~on~/*q*~off~ dimensionless.

Since there are two binding steps necessary to cross-link two PIF-TCRs, with each step potentially having its own off-rate, there are also two effective light-dependent off-rates,$$k_{off}^{\ast}\left( I \right) = k_{off} + k_{i}\left( I \right),$$$$q_{off}^{\ast}\left( I \right) = q_{off} + k_{i}\left( I \right).$$

Consequently, both affinities, the binding affinity from solution *K* and the (dimensionless) cross-link affinity *Q*, are affected by the light intensity,$$K^{*}\left( I \right) = {k_{on}/{k_{off}^{*}\left( I \right)}},$$$$Q^{*}\left( I \right) = {q_{on}/{q_{off}^{*}\left( I \right)}}.$$

To find the steady-state density of unbound PIF-TCRs, *T*~eq~(*P*~ON~,*I*), we define *ξ*(*I*) = *k*~i~/*k^\*^*~off~(*I*) and solve the following, effectively quadratic, equation for *T*,$$1 = T + K^{*}\left( I \right) \bullet P_{ON} \bullet T + \frac{2P_{2} + K_{L}P_{ON}\xi\left( I \right)}{1 + \left\lbrack {1 + K_{L} + Q^{*}\left\lbrack I \right\rbrack \bullet T} \right\rbrack\xi\left( I \right)}Q^{*}\left( I \right) \bullet K^{*}\left( I \right) \bullet T^{2}.$$

In the later section on model fitting, we need the steady-state amounts of cross-linked PIF-TCRs, *y*~X-Link~ = 2 *y*~2,2,eq~, and bound PhyB ligands, *y*~bound~ = *y*~1,1,eq~ + *y*~2,1,eq~ + *y*~2,2,eq~, which are given by,$$y_{X - Link}\left( {P_{ON},P_{2},I} \right) = \frac{\left\lbrack {2P_{2} + K_{L}P_{ON}\xi\left\lbrack I \right\rbrack} \right\rbrack Q^{*}\left( I \right) \bullet K^{*}\left( I \right) \bullet {T_{eq}\left( {P_{ON},I} \right)}^{2}}{1 + \left\lbrack {1 + K_{L} + Q^{*}\left\lbrack I \right\rbrack \bullet T_{eq}\left\lbrack {P_{ON},I} \right\rbrack} \right\rbrack\xi\left( I \right)},$$$$y_{bound}\left( {P_{ON},P_{2},I} \right) = 1 - T_{eq}\left( {P_{ON},I} \right) - y_{X - Link}\left( {P_{ON},P_{2},I} \right).$$

Kinetic proofreading of TCR-ligand binding by T cells {#s11-1}
-----------------------------------------------------

To carry out their immunological functions properly, T cells must reliably distinguish between foreign (i.e., stimulatory) and self (i.e., non-stimulatory) ligands, even if foreign ligands are buried in a large pool of self ligands. Several models exist in which the off-rate of the ligand-TCR interaction plays a key role in this discrimination ([@bib6]; [@bib16]; [@bib25]; [@bib44]; [@bib54]; [@bib62]), and the underlying mechanisms are commonly referred to as kinetic proofreading (KPR). Although these models differ in the level of detail by which intracellular processes are accounted for, they share the property that downstream signaling is only initiated if the TCR can complete all processes the KPR mechanism comprises. For this to be accomplished, the ligand-TCR complex must sustain a TCR conformation/arrangement ([@bib28]; [@bib53]; [@bib74]) that triggers the KPR processes sufficiently long; premature decay of this active TCR conformation leads to an instant reversion of all KPR modifications acquired so far. Thus, the KPR time *τ*~KPR~ sets a threshold for the half-life of the active TCR conformation *τ*~active~. It is this common aspect of the different KPR mechanisms that is the subject of interest in this work.

To quantify the effect of KPR on signal initiation, we take the probability of completing all KPR processes, *α*~KPR~, to be a strictly increasing function of *τ*~active~ that assumes its mid-value 0.5 if *τ*~active~ = *τ*~KPR~. A convenient choice for such a function is given by$$\alpha_{KPR}\left( \tau_{active} \right) = 2^{- \tau_{KPR}/\tau_{active}},$$for which *α*~KPR~ → 1 if *τ*~active~ \>\> *τ*~KPR~, and *α*~KPR~ → 0 if *τ*~active~ \<\< *τ*~KPR~. Note that *α*~KPR~ = 1 if *τ*~KPR~ = 0, which reflects the absence of a KPR mechanism, because in this case the active TCR conformation initiates downstream signaling instantly.

The relation between the half-life of the active TCR conformation and the off-rate of the ligand-TCR interaction, *k*~off~, and its half-life *τ*~D~ = ln(2)/*k*~off~, depends on the way the TCR is stimulated. In the simplest case, ligands bind TCRs monovalently with this complex being already the active conformation (this might be the case with membrane-bound ligands). Then, *τ*~active~ = *τ*~D~. However, the experimental setup used in this work requires cross-linking of TCRs, i.e., bivalent binding of the soluble ligand ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}), for inducing TCR signaling and thus establishing the active TCR conformation. Because the active TCR conformation of two cross-linked TCRs decays if one of the two subunits dissociates, see [Equation (15c)](#equ20){ref-type="disp-formula"}, the half-life of the active TCR conformation is given by$$\tau_{active}\left( I \right) = \frac{ln\left( 2 \right)}{2q_{off}^{*}\left( I \right)},$$where [Equation (16b)](#equ23){ref-type="disp-formula"} has been used. Note that [Equation (21)](#equ30){ref-type="disp-formula"} is specific for soluble ligands and might assume a different form if ligands are membrane- or surface-bound.

Example: Kinetic proofreading as proposed by McKeithan {#s12}
======================================================

To illustrate how an expression of the form [Equation (20)](#equ29){ref-type="disp-formula"} arises in a KPR mechanism, we use the model proposed by McKeithan as an example ([@bib54]). In this version receptors assuming an active TCR conformation are subject to sequential modifications each taking place with identical rates *k*~p~ ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Downstream signaling is initiated only if *n* modifications are completed. However, if the active TCR conformation decays at any stage with rate *k*~dec~, all modifications acquired so far are lost rapidly.

The half-life of the active TCR conformation is given by *τ*~active~ = ln(2)/*k*~dec~, and the time to acquire a single modification by *τ*~p~ = 1/*k*~p~. Since *n* modifications are required for signaling, the average time from forming the active TCR conformation to establishing a signal is *τ*~KPR~ = *n τ*~p~ ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). The steady-state fraction of receptors in the active TCR conformation exhibiting all *n* modifications is then given by$$\alpha_{n}\left( \tau_{active} \right) = \left( \frac{\tau_{active}}{\tau_{active} + \frac{ln(2)}{n}\tau_{KPR}} \right)^{n}.$$

We consider the case *n* \>\> 1, since the number of KPR processes involved in signal initiation is typically considered to be rather large. This gives$$\alpha_{n}\left( \tau_{active} \right) \approx \left( {1 - \frac{ln(2)\tau_{KPR}}{n\,\tau_{active}}} \right)^{n}.$$

In the limit of infinitely many modification steps, the KPR term becomes$$\alpha_{\infty}\left( \tau_{active} \right) = 2^{- \tau_{KPR}/\tau_{active}},$$in agreement with [Equation (20)](#equ29){ref-type="disp-formula"}. The KPR terms of McKeithan's version for different values of *n* are shown in [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}. The similarities between the curves shows that [Equation (24)](#equ33){ref-type="disp-formula"} provides a good description independent of *n*.

Determining the PhyB conversion dynamics {#s12-1}
----------------------------------------

Prior to the exposure of the PhyB ligands to the T cells, nearly all PhyB subunits were initially in the OFF state, and the PhyB ligands were illuminated with a certain intensity of light of 660 nm wavelength to convert PhyB subunits to the ON state. This process is described by [Equations (13)](#equ16){ref-type="disp-formula"}. For the binding and calcium measurements ([Figure 7---figure supplements 4](#fig7s4){ref-type="fig"} and [Figure 6D](#fig6){ref-type="fig"}), the duration of pre-illumination was chosen sufficiently long to reach equilibrium as given by [Equations (14)](#equ17){ref-type="disp-formula"}. From the data at *I* = 0 of these calcium measurements, we can infer the relation between the calcium signal and the corresponding concentrations of the different PhyB forms in darkness, i.e., we consider [Equations (18)](#equ26){ref-type="disp-formula"} and [Equations (19a)](#equ27){ref-type="disp-formula"} for *I* = 0. Stopping the pre-illumination with intensity *I* at some time point *T*~stop~ before the equilibrium of PhyB conversion was reached trapped the concentrations of the different PhyB forms in a state that is described by [Equations (13)](#equ16){ref-type="disp-formula"} evaluated at *T*~stop~ and intensity *I*. The corresponding calcium response was again described by [Equations (18)](#equ26){ref-type="disp-formula"} and [Equations (19a)](#equ27){ref-type="disp-formula"} for *I* = 0 (because we switched to darkness after pre-illumination), but this time the PhyB concentrations did not assume their equilibrium values, [Equations (13)](#equ16){ref-type="disp-formula"}. We can thus deduce the relation between *T*~stop~ and the concentrations of the different PhyB forms for intensity *I*. Using different time points revealed the kinetics of PhyB conversion at the given intensity allowing for inferring the corresponding value of the conversion rate *k*~i~. Repeating the protocol for a different intensity gives the same result but with changed rate *k*~i~ according to [Equation (1b)](#equ2){ref-type="disp-formula"}. Importantly, these results do not depend on the total PhyB concentration. This was indeed found experimentally ([Figure 8B](#fig8){ref-type="fig"}) and thus used to determine the conversion rates.

T cell activation and model fitting {#s12-2}
-----------------------------------

The central question of this work is whether T cells exploit a KPR mechanism. As shown above, the principal parameter of the KPR mechanism is its duration *τ*~KPR~, with *τ*~KPR~ = 0 corresponding to no KPR mechanism being present. The active TCR conformation, which triggers a potential KPR mechanism and ultimately initiates downstream signaling, is given by TCRs bivalently bound by PhyB tetramers, i.e., cross-linked TCRs. The calcium response is thus taken to be proportional to the number of cross-linked TCRs,$$\left. {Ca}^{2 +}\left( {P_{ON},P_{2},I} \right) \right.\sim\alpha_{KPR}\left( {\tau_{active}\left( I \right)} \right) \bullet y_{X - Link}\left( {P_{ON},P_{2},I} \right).$$

The KPR term is given by [Equation (20)](#equ29){ref-type="disp-formula"}. The half-life of the active TCR conformation appearing in the KPR term of relation [Equation (20)](#equ29){ref-type="disp-formula"} is given by [Equation (21)](#equ30){ref-type="disp-formula"}. The cross-link term is determined by [Equations (18)](#equ26){ref-type="disp-formula"} and [Equations (19a)](#equ27){ref-type="disp-formula"}, and binding is described by [Equations (18)](#equ26){ref-type="disp-formula"} and [Equations (19b)](#equ28){ref-type="disp-formula"}. The total amount of PhyB in the ON state, *P~ON~*, and the concentration of PhyB with both PhyB molecules in the ON state, *P~2~*, are either determined by [Equations (13)](#equ16){ref-type="disp-formula"} or by [Equations (14)](#equ17){ref-type="disp-formula"}, depending on whether PhyB had been pre-illuminated with short pulses of 660 nm light to reveal the PhyB conversion kinetics ([Figure 8A and B](#fig8){ref-type="fig"}) or with an extended pulse to establish the PhyB equilibrium partition.

For the choice of the independent model parameters, it is convenient to re-define the conversion rate *k*~i~, [Equation (1b)](#equ2){ref-type="disp-formula"}, by$$k_{i}\left( I \right) = k_{off} \bullet I/I_{0}.$$

The parameter *I*~0~ is the intensity at which the conversion rate *k*~i~ equals *k*~off~. We further define *τ*~D~ = ln(2)/*k*~off~, the half-life of the PhyB ON-PIF-TCR complex in darkness, and *γ*~off~ = *q*~off~/*k*~off~ to quantify how distinct the off-rates, given by [Equation (16)](#equ22){ref-type="disp-formula"}, are. With these definitions, the set of independent model parameters used for fitting is given in the following table:

  Parameter                      Unit   Description
  ------------------------------ ------ --------------------------------------------------------------------------------
  *K*~D~ = *k*~off~/*k*~on~      nM     Dissociation constant of PhyB ON-PIF-TCR complex (darkness)
  *Q* = *q*~on~/*q*~off~         --     Association constant of multivalent binding step (darkness)
  *τ*~D,PhyB~ = ln(2)/*k*~off~   s      Half-life of PhyB ON-PIF-TCR complex (darkness)
  *γ*~off~ = *q*~off~/*k*~off~   --     Distinction of off-rates of mono- and multivalent dissociation
  *I*~0~                         --     Intensity at which *k*~i~ = *k*~off~
  *τ*~KPR~                       s      Duration of KPR mechanism (=threshold half-life of the ligand-TCR interaction)

We fitted the models to the data using the maximum likelihood principle. For the binding data we used the estimated standard errors as obtained from the data. For the calcium signal we assumed an error model with a common coefficient of variation for all calcium data. All data (binding + all calcium measurements) were fitted simultaneously, providing a sufficiently large sample size (in total 130 data points).

To answer the question whether T cells exploit a KPR mechanism, we tested the hypothesis *τ*~KPR~ = 0 against *τ*~KPR~ \> 0 by fitting the corresponding model to the data. Both fits were performed assuming *γ*~off~ = 1, i.e., we assumed that both off-rates were identical. A likelihood ration test revealed strong support for the alternative hypothesis *τ*~KPR~ \> 0 (p\<10^−6^, [Figure 7D](#fig7){ref-type="fig"}), showing the necessity to include a KPR mechanism in order to explain the data ([Figures 7E,F](#fig7){ref-type="fig"} and [8B](#fig8){ref-type="fig"}).

To this end, we assumed *γ*~off~ = 1. Because distinct off-rates imply a distinct dependence of the affinities [Equation (17)](#equ24){ref-type="disp-formula"} on the intensity *I*, demanding *γ*~off~ = 1 if no KPR mechanism is considered might be too restrictive for explaining the data (if *γ*~off~ ≠ 1 were actually the case), and a KPR mechanism could falsely be inferred. To avoid such a false-positive, we also considered the case *γ*~off~ ≠ 1 without a KPR mechanism. This additional degree of freedom, however, lead to no improvement of the fit ([Figure 7---figure supplement 5](#fig7s5){ref-type="fig"}), which we take as further support for the existence of a KPR mechanism.

The parameter uncertainties of the model (*τ*~KPR~ \> 0 and *γ*~off~ = 1), expressed as 95% confidence intervals (95% CIs), were computed using the profile likelihood method ([@bib59]; [@bib82]). All parameters were identifiable, i.e., have an upper and lower bound ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). This shows that the data were highly informative on the parameter values. The best-fit values and the lower and upper bounds of the 95% CIs are given in the table below:

  Parameter \[unit\]    Best-fit value   Lower bound   Upper bound
  --------------------- ---------------- ------------- -------------
  *K*~D~ \[nM\]         22               10            46
  *Q*                   11               6             23
  *τ*~D,PhyB~ \[s\]     40               15            150
  *I*~0~ \[% of max\]   2                1             3.5
  *τ*~KPR~ \[s\]        8                3             19

A central assumption made in this study is that the modifications of the KPR mechanism are quickly removed upon dissociation. However, fast rebinding of the just dissociated ligand effectively increases the half-life sensed by a KPR mechanism ([@bib5]; [@bib29]). Following the arguments in [@bib29], we calculate the expected number of rebindings in our system. The binding state triggering KPR in our model is two TCRs cross-linked by PhyB tetramers. Thus, if one TCR dissociates from PhyB, the other TCR remains bound and both TCRs become subject to complete modification removal unless quick rebinding occurs. Assuming the diffusivities of TCR and PhyB-bound TCR to be the same, the average number of rebindings, *N^\*^*, is given by (see [Equation (3)](#equ4){ref-type="disp-formula"} in [@bib29]),$$N^{*} = \frac{q_{on}}{4\pi D_{TCR}},$$with *D~TCR~* to diffusivity of TCRs. Using the best-fit value *q~on~* = 0.19 s^−1^ and the values given in [@bib29] for the TCR diffusivity and TCR density, we find *N^\*^*=0.02. This shows that rebinding can be neglected in our system.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Optogenetic control shows that kinetic proofreading regulates the activity of the T cell receptor\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Arup Chakraborty as the Senior Editor and Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Please aim to submit the revised version as a Tools and Resources paper (see comment below).

Summary:

The authors construct a light operated TCR using PhyB tetramers and a TCR modified with the PIF ligand and GFP. PhyB interaction with PIF is 100% turned off by far red light and 80% activated by red light, with the 20% off state in red light due to a probability of red light also turning the PhyB off. In the dark, the molecules maintain their state with a slow dark reversion of the off state. They trigger Jurkat cells expressing the PIF-TCR with the PhyB tetramers in on state and observe Calcium flux. They then note that 660 nm excitation drives an accelerated dissociation in proportion to intensity without changing the on-rate. They accelerate the dissociation with brighter red light to generate a dataset to test the kinetic proofreading model. The data and model suggest that in the conditions tested, the relevant time frame for interaction with the receptor that enables a calcium flux is 16 s.

This system has excellent properties for controlling kinetics using light. One might expect light to be used for spatial control, so its novel to apply this effectively to a problem in kinetic discrimination. Additional work would be needed to understand how this relates to selection thresholds, but together with the paper from the Weiner lab, this paper makes a strong case that optical control will be a powerful tool for understanding the role of kinetics in immunoreceptor signaling. As a technical paper that develops a tool, this is an interesting paper and could be published in the Tools and Resources category.

We do not think that the paper resolves the question of how kinetic proofreading occurs in any comprehensive way, which is what the authors set out to address. A number of technical points about the method need to be addressed. Furthermore, somewhat disturbingly, the vast literature in the field is cited in a selective manner. Below, we provide guidance on both these important issues.

Essential revisions:

1\) The statements about affinity are too simplistic in the current understanding of the TCR-pMHC interactions. We suggest they replace affinity with potency (meaning functional potency).

2\) When you introduce PhyB-PIF interaction rules you should state the affinity of the 100% on state. From PMID: 19749742 seems to be 20-100 nM in vivo. Would this allow them to load a cell with soluble PhyB and study the rate of dissociation, perhaps in a flow cell by microscopy? It would be fantastic to have a monomeric dissociation rate under different illumination conditions for the modeling.

3\) Would it be possible to pre-load the tetramer to the cells to initiate a signaling condition and then illuminate to different intensities of 660 light to change the signaling state? It's possible that already bound tetramers would remain bound even as the PhyB starts to cycle faster and this may result in a reset of signaling- loss with faster cycling, for example. Alternatively, could the authors link the PhyB to increase the valency such that the change in off-rate would not impact binding (due to greater rebinding). Perhaps a quantum dot or liposome decorated with multiple PhyB could be use employed. See: PMID: 17077145 or PMID: 9300688 for examples. These points need to be discussed.

4\) The claim that you only affect half-life and no other parameter with the optogenetic method you employ is not supported by the data. The LOV2 system requires a conformational change to get the dissociation you need to end engagement (this is clearly stated in the text) and hence, you cannot know that the force of CAR interaction with the ligand is not changed in blue light when this conformational change takes place. Establishing this claim for no force change requires a direct test a la Chen Zhu\'s method to determine if this fundamental postulate of the method is true or not. This point needs to be discussed.

5\) A number of relevant papers need to be cited that are pertinent, and the present results related to these studies. A small sampling of the missing literature are:a) The work from the Davis lab from several years ago on using caged pMHCs that were sensitive to light, which allowed measurements that described the speed at which signals propagate downstream.b) The role of rebinding that allows ligands with short half-lives to signal, described by work from eight years ago by Van der Merwe and co-workers (Immunity) and Huseby and co-workers (PNAS).c) The role of co-receptors, amount of active Lck and diffusion in kinetic proof reading described by Stepanek et al., 2014.d) You also ignore the data the Germain lab, and others, have presented showing that the same ab TCR signals differently in DP thymocytes vs. mature cells \[in particular, allows meaningful propagation of signals for gene expression in DP with pMHC ligands incapable of electing the same response or biochemical changes in a mature T cell\], meaning that intracellular events can control signal propagation separately from occupancy, half-life or mechanosensing.

6\) The model for proofreading is a bit strange. Many people have made models that are far more realistic and incorporate feedback, including several papers from the Germain lab (Madrenas et al., 1995; Madrenas et al., 1997; Altman and Germain, 2005 and Nature. 2002 Nov 28;420(6914):429-34), Chakraborty and Palmer, Chakraborty and Weiss, and the more theoretical efforts by Murugan, Huse, and Leibler. These papers should at least be cited and briefly discussed.

7\) The estimate of 3 proofreading steps is undoubtedly wrong. The various steps do not have the same time scales and there are feedback loops. These effects make the model\'s fit to obtain n very difficult to interpret. This part needs to be deleted.

10.7554/eLife.42475.064

Author response

> Summary:

The authors construct a light operated TCR using PhyB tetramers and a TCR modified with the PIF ligand and GFP. PhyB interaction with PIF is 100% turned off by far red light and 80% activated by red light, with the 20% off state in red light due to a probability of red light also turning the PhyB off. In the dark, the molecules maintain their state with a slow dark reversion of the off state. They trigger Jurkat cells expressing the PIF-TCR with the PhyB tetramers in on state and observe Calcium flux. They then note that 660 nm excitation drives an accelerated dissociation in proportion to intensity without changing the on-rate. They accelerate the dissociation with brighter red light to generate a dataset to test the kinetic proofreading model. The data and model suggest that in the conditions tested, the relevant time frame for interaction with the receptor that enables a calcium flux is 16 s.

We thank you for this nice summary. Indeed, we found that in our system one individual ligand-TCR interaction has to have a half-life of 16 s for a half maximal response. However, we use a soluble ligand tetramer for which it has been shown that they need to bind at least bivalently to trigger the TCR (Boniface et al., 1998; Cochran et al., 2000; Minguet et al., 2007). In agreement with this, we showed that monomeric PhyB was not able to stimulate the GFP-PIF^S^-TCR (new Figure 5---figure supplement 1C). Thus, the relevant kinetic proofreading half-life is the one of bivalent binding and not of monovalent binding. For bivalent binding the relevant time frame is 8 s (modified Figures 8D and 9). We have elaborated on this in the new version and have changed the KPR time from 16 s to 8 s to avoid misunderstandings.

> This system has excellent properties for controlling kinetics using light. One might expect light to be used for spatial control, so its novel to apply this effectively to a problem in kinetic discrimination. Additional work would be needed to understand how this relates to selection thresholds, but together with the paper from the Weiner lab, this paper makes a strong case that optical control will be a powerful tool for understanding the role of kinetics in immunoreceptor signaling. As a technical paper that develops a tool, this is an interesting paper and could be published in the Tools and Resources category.
>
> We do not think that the paper resolves the question of how kinetic proofreading occurs in any comprehensive way, which is what the authors set out to address. A number of technical points about the method need to be addressed. Furthermore, somewhat disturbingly, the vast literature in the field is cited in a selective manner. Below, we provide guidance on both these important issues.

We thank the reviewers for acknowledging the novelty of our work. As suggested we submit now as a Tools and Resources paper. We have extensively included discussion of the literature (see below).

> Essential revisions:
>
> 1\) The statements about affinity are too simplistic in the current understanding of the TCR-pMHC interactions. We suggest they replace affinity with potency (meaning functional potency).

We agree with the reviewer that the term "affinity" is too simplistic, if it is the only one used to describe TCR-pMHC interactions. In particular, if more complex interactions -- such as participation of co-receptors or multivalent binding -- are to be summarized by a single parameter, terms like "potency" or "apparent affinity" are more appropriate. However, please note that in our case co-receptors are not present. Further, in our mathematical model, which is based on mass action kinetics and includes multivalent binding, we use the term "affinity" (denoted by K in the manuscript) exclusively to describe binding of PhyB to PIF-TCR from solution. (This is in line with the common usage of the term "affinity", which refers to (the inverse of) the dissociation constant K~D~ of a binding reaction A+B ⇔ AB.) The formation of a bivalent binding state (i.e., two PIF-TCRs being simultaneously bound to the same PhyBt) is described by a "cross-link affinity", denoted by Q in the manuscript. Thus, we describe equilibrium binding by two parameters, with the parameter K being in line with the common usage of the term "affinity". Hence, we opted to keep our nomenclature of "affinity" and "cross-link affinity". However, we included the following sentence when talking about pMHC-TCR and not PhyB-TCR interactions:

"Note that in case of pMHC binding to T cells other processes than the pure pMHC-TCR interaction are involved, such as interactions with the co-receptors CD8 or CD4; thus, the terms 'apparent affinity' or 'potency' might be more suitable when describing these complex binding events."

> 2\) When you introduce PhyB-PIF interaction rules you should state the affinity of the 100% on state. From PMID: 19749742 seems to be 20-100 nM in vivo. Would this allow them to load a cell with soluble PhyB and study the rate of dissociation, perhaps in a flow cell by microscopy? It would be fantastic to have a monomeric dissociation rate under different illumination conditions for the modeling.

The suggestion to measure the PhyB dissociation from our GFP-PIF^S^-TCR cells is well taken. Unfortunately, it was technically challenging for us to determine this dissociation rate experimentally.

Firstly, in order to detect monomeric PhyB, we cloned a chimeric protein comprising PhyB fused to the fluorescent protein mCherry. However, the recombinant expression of this chimeric protein in *E. coli* was very inefficient and yielded a variety of truncated proteins. Thus, we could not use this approach.

Secondly, in our lab we have not established a microscopic flow cell assay and therefore attempted to measure PhyB dissociation from the cells by flow cytometry by using the biotinylated, His~6~-tagged PhyB monomers. After fixation, we aimed to detect PhyB with fluorophore-coupled Streptavidin or with an anti-His~6~ antibody. However, in both cases the ratio of PhyB signal to background fluorescence was too low to reliably quantify the amount of bound PhyB. Note, that in the manuscript we have used PhyB tetramers for the flow cytometry stainings.

Thirdly, we quantified accumulation of dissociated PhyB in the cell supernatant by ELISA. These experiments were of low temporal resolution and did not provide an adequate dynamic range between the two extremes of maximally bound and maximally dissociated PhyB. Hence, we are not convinced that these results are of sufficient quality to include them in the manuscript. We think that the dissociation rate derived from the mathematical modelling of our datasets is a better estimation of the actual value than the aforementioned approaches. This is also reflected in the high similarity of our estimated value for the PhyB to PIF affinity (22 nM, 95% CI 10-46 nM) compared to published estimates (20-100 nM).

> 3\) Would it be possible to pre-load the tetramer to the cells to initiate a signaling condition and then illuminate to different intensities of 660 light to change the signaling state? It's possible that already bound tetramers would remain bound even as the PhyB starts to cycle faster and this may result in a reset of signaling- loss with faster cycling, for example. Alternatively, could the authors link the PhyB to increase the valency such that the change in off-rate would not impact binding (due to greater rebinding). Perhaps a quantum dot or liposome decorated with multiple PhyB could be use employed. See: PMID: 17077145 or PMID: 9300688 for examples. These points need to be discussed.

As suggested, we have pre-loaded the tetramer to the cells to initiate Ca^2+^ signaling and then illuminated with different intensities of 660 light to change the signaling state. We find that a faster cycling between the PhyB ON and OFF states (shorter half-life of binding) was able to stop a signal, similar as when we removed the ligand tetramer with 740 light. Interestingly, the threshold intensity of 660 light was the same as for induction of signaling, namely 3% that corresponds to a half-life of 8 s. This experiment is now included in new Figure 6---figure supplement 1B and C and described and discussed in the fourth paragraph of the subsection "The intensity of continuous 660 nm light determines GFP-PIF^S^-TCR activation".

Since this experiment resulted in a clear cut result, we did not do experiments to change the valency of PhyB; except that we included a new experiment with PhyB monomers (new Figure 5---figure supplement 1C).

> 4\) A number of relevant papers need to be cited that are pertinent, and the present results related to these studies. A small sampling of the missing literature are:a) The work from the Davis lab from several years ago on using caged pMHCs that were sensitive to light, which allowed measurements that described the speed at which signals propagate downstream.b) The role of rebinding that allows ligands with short half-lives to signal, described by work from eight years ago by Van der Merwe and co-workers (Immunity) and Huseby and co-workers (PNAS).c) The role of co-receptors, amount of active Lck and diffusion in kinetic proof reading described by Stepanek et al., 2014.d) You also ignore the data the Germain lab, and others, have presented showing that the same ab TCR signals differently in DP thymocytes vs. mature cells \[in particular, allows meaningful propagation of signals for gene expression in DP with pMHC ligands incapable of electing the same response or biochemical changes in a mature T cell\], meaning that intracellular events can control signal propagation separately from occupancy, half-life or mechanosensing.

We extended the Introduction and Discussion to discuss the literature more thoroughly as suggested (see also next point). We apologize for not having covered the literature well before. This was due to the extremely short article format we had chosen.

> 5\) The model for proofreading is a bit strange. Many people have made models that are far more realistic and incorporate feedback, including several papers from the Germain lab (Madrenas et al., 1995; Madrenas et al., 1997; Altman and Germain, 2005 and Nature. 2002 Nov 28;420(6914):429-34), Chakraborty and Palmer, Chakraborty and Weiss, and the more theoretical efforts by Murugan, Huse, and Leibler. These papers should at least be cited and briefly discussed.

In the Introduction section we have now discussed the work where kinetic proofreading models included feedback and feed-forward loops:

"The KPR model has also been extended to include feedback and feed-forward loops in the signaling network below the TCR (Altan-Bonnet and Germain, 2005; Chakraborty and Weiss, 2014; Dushek et al., 2011; Lever et al., 2016; Rabinowitz et al., 1996). \[...\] At the same time, the high sensitivity of the T cells towards low numbers of ligands (1-10 molecules) was retained (Irvine et al., 2002; Purbhoo et al., 2004)."

> 6\) The estimate of 3 proofreading steps is undoubtedly wrong. The various steps do not have the same time scales and there are feedback loops. These effects make the model\'s fit to obtain n very difficult to interpret. This part needs to be deleted.

Our conclusion was that *at least* 3 proofreading steps have to occur and not that 3 steps occur. However, we agree with the reviewer that the KPR model underlying the estimate of proofreading steps (McKeithan, 1995) is too simplistic, and we have thus deleted our conclusion about the number of proofreading steps.
